Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial ‘in hibernation’, ready for rapid activation

Wei Shen Lim, Clare Brittain, Lelia Duley, Sheila Edwards, Stephen Gordon, Alan Montgomery, Jonathan Nguyen-Van-Tam, Robert Read, Diane Whitham, David Whynes, Mark Woodhead and Dan Wootton
Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial ‘in hibernation’, ready for rapid activation

Wei Shen Lim,1* Clare Brittain,2 Lelia Duley,2 Sheila Edwards,3 Stephen Gordon,4 Alan Montgomery,2 Jonathan Nguyen-Van-Tam,5 Robert Read,6 Diane Whitham,2 David Whynes,7 Mark Woodhead8 and Dan Wootton9

1Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK
2Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK
3British Thoracic Society, London, UK
4School of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool, UK
5Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK
6Faculty of Medicine, University of Southampton, Southampton, UK
7School of Economics, University of Nottingham, Nottingham, UK
8Respiratory Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
9Institute of Infection and Global Health, University of Liverpool, Liverpool, UK

*Corresponding author

Declared competing interests of authors: WSL reports an unrestricted, independent, investigator-initiated research grant from Pfizer, outside the field of influenza. JSN-V-T reports grants from GlaxoSmithKline, grants from F Hoffmann–La Roche, and non-financial support from European Scientific Working Group of Influenza, outside the submitted work. In addition, JN-V-T was employed by SmithKline Beecham (now a part of GlaxoSmithKline – manufacturer of zanamivir and influenza vaccines) from 2000 to 2001, and by Roche Products Ltd (manufacturer of oseltamivir) from 2001 to 2002; he has held no shares, share options or pension rights in either company since 2004. He performed paid consultancy for both companies and several other influenza vaccine manufacturers in the period 2008–10 (all of these lying outside the ICJME 36-month official window of declaration but declared here for completeness). JN-V-T’s brother is a current employee of GlaxoSmithKline but does not work in an influenza-related field.

Published February 2015
DOI: 10.3310/hta19160
This report should be referenced as follows:


*Health Technology Assessment* is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE*, *Science Citation Index Expanded* (SciSearch®) and *Current Contents®/Clinical Medicine*. 
Health Technology Assessment

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 11/46/14. The contractual start date was in December 2012. The report detailing the set up phase and initial outcomes began editorial review in November 2014 and was accepted for publication in January 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report. Should the study progress further, the full report will be published in the HTA journal.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2015. This work was produced by Lim et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact:  nihredit@southampton.ac.uk
Abstract

Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial ‘in hibernation’, ready for rapid activation

Wei Shen Lim,1* Clare Brittain,2 Lelia Duley,2 Sheila Edwards,3 Stephen Gordon,4 Alan Montgomery,2 Jonathan Nguyen-Van-Tam,5 Robert Read,6 Diane Whitham,2 David Whynes,7 Mark Woodhead8 and Dan Wootton9

1Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK
2Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK
3British Thoracic Society, London, UK
4School of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool, UK
5Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK
6Faculty of Medicine, University of Southampton, Southampton, UK
7School of Economics, University of Nottingham, Nottingham, UK
8Respiratory Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
9Institute of Infection and Global Health, University of Liverpool, Liverpool, UK

*Corresponding author weishen.lim@nuh.nhs.uk

Background: There are no completed randomised trials of the use of corticosteroids in patients with severe influenza infection. Corticosteroid use in influenza is widespread, non-systematic and marked by controversy. A recent meta-analysis of observational studies of adjuvant corticosteroids in influenza found an association with increased mortality but there were important concerns regarding the risks of bias.

Objectives: To (1) evaluate whether or not low-dose corticosteroids given as an adjunct to standard treatment is beneficial in patients who are hospitalised with severe pandemic influenza and (2) develop an ‘off-the-shelf’ clinical trial that is ready to be activated in a future pandemic.

Design: Multicentre, pragmatic, blinded, randomised placebo-controlled trial.

Setting: Thirty to 40 hospitals in the UK.

Participants: Adults (≥ 16 years) admitted to hospital with an influenza-like illness during a pandemic.

Intervention: Five-day course of dexamethasone (Dexsol®, Rosemont Pharmaceuticals Ltd) 6 mg daily, started within 24 hours of admission.

Main outcome measure: Admission to Intensive Care Unit, or death, within 30 days of admission to hospital.
Results: This trial has not yet been activated. It is currently set up with full ethics and regulatory approvals in place, ready for rapid activation at the onset of the next pandemic. Hurdles to setting up a pandemic trial include planning for pandemic-level pressures on UK NHS resources and co-enrolment of patients to multiple pandemic studies, ensuring adequate geographical distribution of participating sites, maintaining long-term low-level engagement with site investigators, addressing future trial-specific training needs of local investigators and resilience planning in trial management. Identified threats to trial delivery include changes to research capabilities or policies during the hibernation phase, lack of staff resources during a pandemic and the influence of media at the time of a pandemic. A mismatch in the approach to informed consent required by current regulations to that preferred by patients and the public was identified.

Conclusions: This study demonstrates that advance set-up of a trial to be conducted during a pandemic, with full regulatory approvals in place, is possible. Regular review during the hibernation phase will be required. This study serves as a model for the development of other ‘off-the-shelf’ trials as part of preparedness planning for public health emergencies.


Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 19, No. 16. See the NIHR Journals Library website for further project information.
Contents

List of tables xi
List of figures xiii
List of abbreviations xv
Plain English summary xvii
Scientific summary xix

Chapter 1 Introduction 1
Corticosteroids in influenza 1
Corticosteroids in pneumonia and sepsis 2
Potential harm of corticosteroids 2
The Adjuvant Steroids in Adults with Pandemic influenza trial 3
Methods 3
  Study design 3
  Participants 3
  Intervention 4
  Control 4
  Materials 4
  Outcomes 4
  Trial oversight 5
  Statistical considerations 5
  Substudy 6

Chapter 2 Results 7
Patient and public involvement regarding trial consent 7
Regulatory approvals 7
NHS permissions 8
Trial activation 9

Chapter 3 Discussion 11
Choice of intervention 11
Hurdles 12
  Pressure on NHS resources 12
  Co-enrolment of patients 12
  Engagement of sites 12
  Site selection 13
  Supply of Investigational Medicinal Product 13
  Training of local investigators 13
  Command and control 13
Threats 14
  Changes during hibernation 14
  Lack of research staff 14
  Written informed consent 14
  Public engagement: social media 15
A model for ‘off-the-shelf’ trials in public health emergencies 15
Chapter 4 Conclusion

Acknowledgements

References

Appendix 1 Protocol

Appendix 2 Consent form

Appendix 3 Information leaflet

Appendix 4 Follow-up questionnaire

Appendix 5 Participating sites
List of tables

TABLE 1 Consent approaches preferred by persons (n = 44) consulted at PPI events 7
List of figures

FIGURE 1  Participating sites in the UK (as of 22 January 2015) 8
# List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASAP</td>
<td>Adjuvant Steroids in Adults with Pandemic influenza</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CLAHRC</td>
<td>Collaboration for Leadership in Applied Health Research and Care</td>
</tr>
<tr>
<td>CLRN</td>
<td>Comprehensive Local Research Network</td>
</tr>
<tr>
<td>CRN</td>
<td>Clinical Research Network</td>
</tr>
<tr>
<td>CTIMP</td>
<td>Clinical Trial of Investigational Medicinal Product</td>
</tr>
<tr>
<td>DSUR</td>
<td>Development Safety Update Report</td>
</tr>
<tr>
<td>HCW</td>
<td>health-care worker</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive Care Unit</td>
</tr>
<tr>
<td>IL</td>
<td>interleukin</td>
</tr>
<tr>
<td>IMP</td>
<td>Investigational Medicinal Product</td>
</tr>
<tr>
<td>ISRCTN</td>
<td>International Standard Randomised Controlled Trial Number</td>
</tr>
<tr>
<td>ITT</td>
<td>intention to treat</td>
</tr>
<tr>
<td>i.v.</td>
<td>intravenous</td>
</tr>
<tr>
<td>MHRA</td>
<td>Medicines and Healthcare Products Regulatory Agency</td>
</tr>
<tr>
<td>MIG</td>
<td>monokine induced by interferon-gamma</td>
</tr>
<tr>
<td>NCTU</td>
<td>Nottingham Clinical Trials Unit</td>
</tr>
<tr>
<td>NIHR</td>
<td>National Institute for Health Research</td>
</tr>
<tr>
<td>PPI</td>
<td>patient and public involvement</td>
</tr>
<tr>
<td>REC</td>
<td>Research Ethics Committee</td>
</tr>
<tr>
<td>RR</td>
<td>risk ratio</td>
</tr>
<tr>
<td>TSC</td>
<td>Trial Steering Committee</td>
</tr>
</tbody>
</table>
Plain English summary

The aims of this study are to (1) find out whether a commonly used steroid (a medicine that reduces inflammation) called dexamethasone, given in addition to the normal treatment for flu, will benefit patients admitted to hospital with flu during a pandemic and (2) set up a trial in advance of a pandemic, which can be put into ‘hibernation’ for rapid activation when required.

The trial will be conducted at approximately 40 hospitals in the UK. Adults admitted with flu in a pandemic will be asked to take part. Participants will be randomly given either a 5-day course of dexamethasone or a matching placebo (dummy medicine without any active ingredients). Information recorded routinely in patients’ medical notes will be used to determine whether or not treatment with dexamethasone reduces the number of patients who die or are admitted to intensive care within 30 days of hospital admission.

The challenges encountered during set-up included:

(a) planning for a period when health-care resources will be exceptionally stretched
(b) ensuring geographical spread of participating hospitals
(c) addressing future training needs of investigators
(d) resilience planning of trial management.

Patients and the public were found to prefer arrangements for giving their consent which current regulations do not permit. Whether or not this will create difficulties in future remains to be determined.

This study demonstrates that advance set-up of a trial with full regulatory approvals in place, is possible; it serves as a model for the development of other ‘off-the-shelf’ trials in public health emergencies.
Scientific summary

Background

The use of corticosteroids in patients with severe sepsis is recommended by international sepsis guidelines. This recommendation is based on evidence from numerous randomised controlled trials and subsequent meta-analyses. In patients who are hospitalised with community-acquired pneumonia, a recent meta-analysis of randomised controlled trials reported a survival benefit from corticosteroid therapy in the subgroup of patients with severe pneumonia. Further large clinical trials are ongoing in the fields of both severe sepsis and community-acquired pneumonia to investigate the role of corticosteroids as adjuvant therapy.

In contrast, there are no completed randomised trials of the use of corticosteroids in patients with pandemic, avian or seasonal influenza infection. Corticosteroid use in influenza is widespread, non-systematic and marked by controversy. A recent meta-analysis of observational studies of adjuvant corticosteroids in influenza found an association with increased mortality but there were important concerns regarding the risks of bias.

Objectives

The aims of the Adjuvant Steroids in Adults with Pandemic influenza (ASAP) trial are to (1) determine whether or not low-dose corticosteroids, given as an adjunct to standard treatment, are beneficial in patients who are admitted to hospital with severe pandemic influenza, and (2) demonstrate that an ‘off-the-shelf’ model for a trial that is designed, set up and ready to activate during a public health emergency is possible.

Methods

The trial study design and planned analyses are described below. Methodological aspects of trial set-up and delivery that are unique to the ‘off-the-shelf’ nature of this study are reported in the next section (see Results).

This is a pragmatic blinded, randomised placebo-controlled trial to determine whether or not during a pandemic, for adults (≥ 16 years) who are admitted to hospital with an influenza-like illness, a 5-day course of dexamethasone (Dexsol®, Rosemont Pharmaceuticals Ltd) started within 24 hours of admission, in addition to standard care, is associated with a lower risk of death or admission to intensive care than placebo. This trial will be conducted at 30–40 sites across the UK during the first wave of the next influenza pandemic and will recruit 2200 participants, probably over a 6-week period.

Adults with a clinical diagnosis of an influenza-like illness at the time of hospitalisation will be eligible for recruitment to the ASAP trial; a laboratory diagnosis of influenza will not be required. The definition of an influenza-like illness will be confirmed at the start of the pandemic and will conform to the definition provided by Public Health England at the time. Adults who are known to be taking or requiring corticosteroids at the time of hospitalisation, and those who are on medication for the treatment of diabetes mellitus, will not be eligible to participate in the trial.
The study intervention is dexamethasone, administered as an oral liquid preparation, 6 mg once daily for 5 days. Dexamethasone 6 mg is equivalent to prednisolone 40 mg or hydrocortisone 160 mg. The study control is a matching placebo, identical in colour, taste and consistency to the intervention. Participants will be randomised (1 : 1 ratio) to receive dexamethasone or placebo. In addition to the intervention/placebo, all patients will receive standard care for influenza, including oxygen supplementation, fluids, antiviral drugs and antibiotic drugs as appropriate.

In a high-severity pandemic, the primary composite outcome is admission to intensive care or death by day 30. In a low- to moderate-severity pandemic, the primary outcome is time to hospital discharge.

A planned early analysis focused on the primary end points will be performed to provide rapid data to the UK Department of Health prior to the start of the second pandemic wave. Pre-planned subgroup analyses will be conducted for the primary outcome, based on the following baseline factors:

1. duration of symptoms
2. clinical diagnosis of pneumonia
3. underlying comorbid illness
4. severity of influenza.

In parallel with the ASAP trial, we have set up a mechanistic substudy to be conducted at six pre-selected trial-participating sites. The substudy will collect biological samples from 200 ASAP trial participants to determine the interaction of steroid therapy and the host, and to apply this in interpreting the clinical outcomes measured. Two blood samples and one nasal swab for subsequent transcriptomic and microbiological testing will be obtained from participants at baseline and 48 hours post first dose of ASAP trial medication.

**Results**

This trial has not yet been activated. The status of the trial at the end of the set-up phase is described, together with results from patient and public involvement (PPI) consultation events and hurdles encountered during trial set-up.

Consultations with patients and the public specifically in relation to the consent process for this trial included events with representatives from charitable organisations related to respiratory disorders, PPI representatives of the East Midlands Collaboration for Leadership in Applied Health Research and Care, a library reading group and members of a town council. The majority view from these consultations was a preference for a clear verbal consent process prior to trial enrolment in contrast with a weightier written consent approach; of 42 persons consulted, only two preferred a written consent approach. Initial opinions from a Research Ethics Committee (REC) also favoured a verbal consent approach. However, current legal regulations required a process of written informed consent for this trial.

This trial has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) (European Union Drug Regulating Authorities Clinical Trials 2013–001051–12) and the South Central – Oxford C REC (13/SC/0436). Global governance checks have been completed in England, Wales and Scotland, enabling sites to issue local UK NHS permissions. The study is registered, with the International Standard Randomised Controlled Trial Number (ISRCTN) registry and will be conducted in accordance with the principles of the Declaration of Helsinki, the standards of Good Clinical Practice (as defined by the International Conference on Harmonisation) and UK regulatory and ethical requirements.
Owing to the lengthy hibernation period, MHRA approval was granted on the condition that a substantial amendment is submitted at the time of activation to confirm that there is no change to the risk–benefit analysis of the trial. The requirement for an annual Development Safety Update Report (DSUR) was waived by the MHRA. In place of this, an annual letter will be sent advising of any changes in risk–benefit analysis of the trial until the trial is activated. Standard DSUR submissions will commence once the trial has been activated.

Twenty-nine sites have been granted NHS site permission and a further 11 sites are in the process of obtaining local approvals (data as of 22 January 2015). These sites cover a wide geographical area across the UK, including most major cities. Trial activation will be at the request of the National Institute for Health Research (NIHR). It is anticipated that recruitment will be completed by the end of the first wave of the pandemic.

The biggest challenge in setting up this trial has been the uncertainty regarding the timing and severity of a future influenza pandemic. Hurdles encountered during trial set-up included (1) planning for pandemic-level pressures on NHS resources; (2) agreeing to co-enrolment of patients to other non-interventional cohort pandemic studies; (3) ensuring adequate geographical distribution of participating sites; (4) maintaining engagement with site investigators with respect to a trial that may not be activated for some years; (5) addressing future trial-specific training needs of local investigators; and (6) resilience planning in trial management.

Identified threats to trial delivery include changes to research capabilities or policies during the hibernation phase and lack of staff resources during a pandemic. Timely and sufficient support by Comprehensive Local Research Network units at all participating sites, not least through the redeployment of research staff during the pandemic, will be critical to the successful delivery of this trial.

**Conclusions**

This is the first multicentre clinical trial that has been set up – to our knowledge – in readiness for rapid activation at the onset of a pandemic. Advance set-up of a pandemic trial with full regulatory approvals in place enables the resolution of many issues at an early stage, outside the ‘heat’ of a pandemic. This study serves as a model for the development of other ‘off-the-shelf’ trials as part of preparedness planning for public health emergencies.

**Trial registration**

This trial is registered as ISRCTN72331452.

**Funding**

Funding for this study was provided by the Health Technology Assessment programme of the NIHR.
Chapter 1 Introduction

Influenza virus infection is associated with a wide spectrum of illness, from no symptoms to pneumonia and death. During a pandemic, most people are likely to experience a minor influenza-like illness, characterised by fever and cough, typically lasting 7–10 days. For pandemic planning purposes, the UK Pandemic Influenza Preparedness Strategy 2011 recommends that an estimated 1–4% of symptomatic patients should be expected to require hospital care. Patients may be admitted to hospital either because of influenza-related exacerbations of underlying co-existing illnesses, such as chronic obstructive pulmonary disease or as a result of complications of influenza infection, such as pneumonia.

Following hospital admission, some patients deteriorate rapidly (within 24 hours) and require Intensive Care Unit (ICU)-level support for respiratory failure. The proportion who might require ICU support in a pandemic is difficult to predict and a range of 15–25% of hospitalised patients has been suggested. In a high-severity pandemic, resource limitations will probably define the upper limit. In the low-severity pandemic of 2009, 17% of hospitalised patients were admitted to level 2 or level 3 care; the median time from symptom onset to ICU admission was 6 days, and from hospital admission to ICU admission was 2 days. Overall, 7% of hospitalised patients with confirmed H1N1 influenza infection died.

Current principles of therapy in the management of adults admitted to hospital with pandemic influenza infection include appropriate fluid replacement, oxygen supplementation, antiviral therapy and organ support, as required. In addition, antibiotic therapy is recommended for all hospitalised adults except previously well adults with only influenza-related acute bronchitis.

Corticosteroids in influenza

The role of corticosteroids in severe influenza infection remains uncertain. During the early phase of illness, influenza A virus infection induces inflammatory [e.g. interleukin 6 (IL-6), IL-8] and T-helper type 1 cell immune responses [e.g. interferon-induced protein 10, monokine induced by interferon-gamma (MIG)], correlating with clinical illness. Hypercytokinaemia is also recognised in patients with H5N1 influenza infection (e.g. IL-6, IL-10, MIG) with the highest levels found in patients who subsequently die. Similar changes have been observed in patients with 2009 pandemic H1N1 infection. Such inflammatory cytokines may suppress the hypothalamic–pituitary–adrenal axis, resulting in relative adrenal insufficiency or competing with intracellular glucocorticoid receptor function, resulting in peripheral tissue steroid resistance. In patients with septic shock and community-acquired pneumonia, corticosteroids in low doses (e.g. hydrocortisone ≤ 300 mg per day or dexamethasone ≤ 11.25 mg/day) downregulates proinflammatory cytokine transcription and has been shown to improve innate immunity.

In clinical practice, corticosteroid use in influenza is widespread, non-systematic and marked by controversy. During the 2009 pandemic, corticosteroid use in critically ill patients with H1N1 influenza was identified in 83 (40%) of 208 patients in a French registry, 107 (44%) of 245 patients in a South Korean cohort study, and 126 (57%) of 220 patients in the European Society of Intensive Care Medicine H1N1 registry. The heterogeneity of these cohort studies and non-randomised study designs preclude any firm conclusions regarding the risks or benefits of corticosteroids in the treatment of influenza. A recent meta-analysis of observational studies of adjuvant corticosteroids in influenza found an association with increased mortality but there were important concerns regarding the risks of bias – in particular, bias arising from confounding by indication (corticosteroids prescribed in the sickest patients as a ‘treatment of last resort’). No completed randomised trials of the use of corticosteroids in patients with pandemic, avian or seasonal influenza infection were identified.
Corticosteroids in pneumonia and sepsis

In patients who are hospitalised with community-acquired pneumonia, trials of adjuvant corticosteroids have reported significant reductions in median length of hospital stay and faster declines in C-reactive protein levels and defervescence.\(^\text{17,18}\) In 2011, a Cochrane systematic review of systemic corticosteroid use in all-cause pneumonia reported no overall mortality benefit, but a reduction in time to resolution of symptoms: in the subgroup of individuals with severe pneumonia, a reduction in the need for mechanical ventilation and improved oxygenation was found.\(^\text{19}\) A more recent meta-analysis,\(^\text{20}\) which included additional randomised controlled trials, reported a survival benefit from corticosteroid therapy in the subgroup of patients with severe pneumonia. Currently, three large randomised controlled clinical trials investigating the effectiveness of adjuvant corticosteroids in community-acquired pneumonia are recruiting; the interventions being tested are prednisolone 50 mg daily for 7 days (ClinicalTrials.gov identifier: NCT00973154), dexamethasone 6 mg daily for 4 days (ClinicalTrials.gov identifier: NCT01743755) and methylprednisolone 40 mg/kg daily in tapering doses over 20 days (ClinicalTrials.gov identifier: NCT01283009).

In adults with septic shock, international sepsis guidelines recommend that low-dose corticosteroids may be considered if fluid resuscitation and vasopressor therapy are inadequate to restore haemodynamic stability.\(^\text{21}\) This recommendation is based on different strands of evidence, including the results from numerous randomised controlled trials and subsequent meta-analyses. In one systematic review\(^\text{22}\) of 12 randomised trials examining the benefit of low-dose corticosteroids [hydrocortisone \(\leq 300\) mg per day (equivalent to dexamethasone \(\leq 11.25\) mg/day)] for \(\geq 5\) days compared with placebo in adults with severe sepsis and septic shock (\(n = 1228\)), 28-day mortality was 37.5% compared with 44.1% [risk ratio (RR) 0.84, 95% confidence interval (CI) 0.72 to 0.97]. However, this finding contrasts with the results of the largest completed trial (Corticosteroid Therapy of Septic Shock), which examined the role of low-dose corticosteroids in patients with septic shock (\(n = 499\)); no significant difference in mortality was evident between corticosteroid and placebo groups (34% vs. 31%).\(^\text{23}\) More recently, a large observational cohort study reported higher overall mortality rates in patients with severe sepsis who received corticosteroids than in those who did not (58% vs. 43%).\(^\text{24}\) The prevailing controversy regarding the role of low-dose corticosteroids in severe sepsis is reflected in the inconsistent and varied use of corticosteroids observed in clinical practice internationally, ranging from 9% to > 60% of patients enrolled in the Promoting Global Research Excellence in Severe Sepsis registry in different countries.\(^\text{24}\) Currently, a further large randomised controlled clinical trial of hydrocortisone in critically ill patients with septic shock is recruiting (target sample size \(n = 3800\)); the intervention is hydrocortisone given as an infusion of 200 mg/day for 7 days (ClinicalTrials.gov identifier: NCT01448109).\(^\text{25}\)

Potential harm of corticosteroids

A systematic review of corticosteroid trials in severe sepsis and septic shock did not identify any increased risk of gastroduodenal bleeding, superinfection or neuromuscular weakness. An association with an increased risk of hyperglycaemia (RR 1.16, 95% CI 1.07 to 1.25) and hypernatraemia (RR 1.61, 95% CI 1.26 to 2.06) was noted.

Of trials in community-acquired pneumonia, Meijvis \textit{et al.}\(^\text{17}\) observed that hyperglycaemia was more common in the treatment group, whereas Snijders \textit{et al.}\(^\text{18}\) noted that the risk of hyperglycaemia requiring additional therapy was non-significantly higher in the treatment group (2.3% of 104 vs. 0.9% of 109; \(p = 0.27\)). Snijders \textit{et al.}\(^\text{18}\) observed an increase in late failures in corticosteroid-treated patients compared with control subjects, described as the need for an additional course of antibiotics, the need for another or prolonged course of prednisolone or development of a parapneumonic effusion necessitating additional therapy. Rebound inflammation as a result of the withdrawal of corticosteroids may explain this finding. In contrast, Meijvis \textit{et al.}\(^\text{17}\) did not observe any differences in late failure. This may relate to relative differences between the half-lives of the different corticosteroids tested (prednisolone vs. dexamethasone).
A meta-analysis of trials investigating the use of corticosteroids in acute bacterial meningitis observed that participants who were treated with corticosteroids had an increase in recurrent fever (RR 1.27, 95% CI 1.09 to 1.47). The rate of persistent fever was lower in the corticosteroid-treated patients (RR 0.29, 95% CI 0.12 to 0.70), whereas other complications (including gastrointestinal haemorrhage) occurred in similar proportions of treatment and control groups.

The Adjuvant Steroids in Adults with Pandemic influenza trial

The Adjuvant Steroids in Adults with Pandemic influenza (ASAP) trial is one of eight National Institute for Health Research (NIHR)-funded pandemic studies set up in readiness for activation at the next pandemic; it is the only randomised trial among the eight. To date, no randomised trials have been conducted successfully during a pandemic. Key barriers to overcome include securing ethics and other regulatory approvals in time, developing the necessary trial procedures and materials to use during a pandemic when health services will already be overstretched, determining how best to offer consent to participants, staff training, and doing all this in time for results to inform patient care within the same pandemic.

The aims of the ASAP trial are therefore to (1) determine whether or not low-dose corticosteroids given as an adjunct to standard treatment is beneficial in patients hospitalised with severe pandemic influenza, and (2) demonstrate that an ‘off-the-shelf’ model for a trial designed, set up and ready to activate during a public health emergency is possible.

Methods

The trial study design and planned analyses are described below. Methodological aspects of trial set-up and delivery that are unique to the ‘off-the-shelf’ nature of this study are reported below (see Results).

Study design

This is a pragmatic, blinded randomised placebo-controlled trial to determine whether or not during a pandemic, a 5-day course of dexamethasone, started within 24 hours of admission, in addition to standard care, is associated with a lower risk of death or admission to intensive care compared with placebo for adults (≥ 16 years) admitted to hospital with an influenza-like illness. This trial will be conducted at 30–40 sites across the UK during the first wave of the next influenza pandemic and will recruit 2200 participants, probably over a 6-week period.

The trial is set out in three phases: set-up, hibernation and activation. A summary of these phases is given in Appendix 1 (see section 6.1, figure 1). During the hibernation phase, regular review of trial procedures and sites will ensure that the trial is maintained in a state in which it can be rapidly activated to start recruitment in the event of a pandemic. When the NIHR activates the trial, it will move to a preactivation phase of 4–6 weeks. This final phase of trial set-up will include production and distribution of the trial drug and trial materials, finalisation of trial procedures, and a check of site readiness prior to beginning recruitment.

Participants

Adults with a clinical diagnosis of an influenza-like illness at the time of hospitalisation will be eligible for recruitment to the ASAP trial; a laboratory diagnosis of influenza will not be required. The definition of an influenza-like illness will be confirmed at the start of the pandemic and will conform to the definition provided by Public Health England at the time.

Adults known to be taking or requiring corticosteroids at the time of hospitalisation, and those on medication for the treatment of diabetes mellitus will not be eligible to participate in the trial.
Participants will be randomised (1 : 1 ratio) to receive dexamethasone or placebo. An overview of the trial design is given in Appendix 1 (see section 6.1, figure 2). Randomisation will be stratified by site. Each site will receive batches of sealed trial treatment packs in a consecutively numbered series. The treatment packs each contain (1) a 75-ml bottle of either dexamethasone 2 mg/5 ml or placebo (sufficient for 5 days of treatment); (2) instructions for the take home pack (for participants discharged within 5 days of admission); and (3) administration instructions. Trial treatment packs will be stored and available in each area where patients with influenza will be admitted during a pandemic. The two treatments, dexamethasone and placebo, are indistinguishable. Allocation to trial treatment will be by taking the next in the series of treatment packs in that area. Participants will be considered to be in the trial once the trial treatment pack label is completed regardless of whether or not they take any allocated treatment.

**Intervention**
The study intervention is dexamethasone administered as an oral liquid preparation, 6 mg once daily for 5 days. Dexamethasone 6 mg is equivalent to prednisolone 40 mg or hydrocortisone 160 mg.

**Control**
The study control is a matching placebo identical in colour, taste and consistency to the intervention.

In addition to the intervention/placebo, all patients will receive standard care for influenza, including oxygen supplementation, fluids, antivirals and antibiotics as appropriate.

**Materials**
Dexsol® (dexamethasone) 2 mg/5 ml oral solution manufactured by Rosemont Pharmaceuticals Ltd (PL 00427/0137) will be used in this trial.

A batch of matching placebo has been manufactured and is being stored by Rosemont Pharmaceuticals Ltd. A new batch of placebo will be manufactured to replace outdated stock as appropriate. Manufacturing time is approximately 4 weeks.

Three manufacturing units have been contracted to provide Investigational Medicinal Product (IMP) packaging and release services.

**Outcomes**
The design and analysis of the trial includes the flexibility to allow for pandemics of different severity. In a high-severity pandemic, the primary composite outcome is admission to intensive care or death by day 30. Secondary outcomes are (1) length of stay in the ICU; (2) readmission to hospital within 30 days of hospital discharge; (3) length of stay in hospital; (4) death within 30 days of admission to hospital; (5) admission to ICU within 30 days of admission to hospital; and (6) general practitioner consultations within 30 days of hospital discharge.

For the purposes of this trial, ‘admission to intensive care’ is defined as provision of level 3 care (usually involving mechanical ventilation); this includes the provision of such care in non-traditional level 3 environments as might be encountered under contingency or crisis situations during a pandemic.27,28 This definition of ‘intensive care’ accords with the Department of Health planning assumptions.29 Most patients who require critical care are likely to be mechanically ventilated at some point; during the low-severity 2009 pandemic, 77% of patients managed in critical care in the UK required advanced respiratory support.30

In a low-/moderate-severity pandemic, the primary outcome is time to hospital discharge, right censored at 30 days.
At the outset of a pandemic, its severity will not necessarily be accurately appreciated. The ASAP trial is planned in anticipation of a high-severity pandemic; this represents the most challenging situation for trial execution and also the situation in which the trial results might have the largest public health impact. In addition, at the start of a pandemic, patients with more severe illness will be more readily identified and recognised compared with patients with mild or subclinical disease, hence potentially masking the true overall nature of the pandemic. Uncertainty regarding the severity of a pandemic will remain until sufficient data are gathered, which may not be until after the end of the first pandemic wave.

A review of pandemic severity will be conducted by the Trial Management Group and Trial Steering Committee (TSC) as the pandemic unfolds. Decisions regarding the final analysis plan and final primary outcome will rest with the TSC. These decisions are expected to be informed by discussions at the time with the Department of Health, NIHR and Public Health England, and will be made before any analyses of trial data are undertaken.

Current modelling estimates from the Department of Health are that for a high-severity pandemic, 35% of those admitted to hospital will die and 25% will be admitted to intensive care. It is anticipated that if these thresholds are not met, the pandemic will not be considered of ‘high severity’. For the purposes of the ASAP trial, thresholds defining a low-severity epidemic compared with a moderate-severity pandemic are less important.

**Trial oversight**

A TSC and a Data Monitoring Committee have been established. Yearly updates will be provided to these committees during the hibernation phase.

**Statistical considerations**

For a high-severity pandemic, with 1100 participants in each arm, the trial will have > 90% power to detect a 20% relative difference given a control event rate of 35%, or 80% power to detect a 15% relative difference given a control event rate of 40%, both with 5% two-sided alpha level. Further details of sample size estimates over a range of possible scenarios is given in Appendix 1 (see section 9.2).

For a low-/moderate-severity pandemic, a hazard ratio of 1.25, indicating an increased risk of discharge at any given time, is considered as the minimum clinically relevant change to detect. With 90% power and 1% two-sided alpha level, 5% censored in the control arm, up to 10% die in hospital in both arms, and 5% non-collection of primary outcome data, about 920 participants are required to be randomised for a low-/moderate-severity pandemic.

The initial target total sample size for the ASAP trial is 2200 participants. If the pandemic is of low or moderate severity, it is likely that fewer than 2200 participants will be randomised during the first wave of approximately 6 weeks’ duration, although this definition will not be available until after the end of the first wave. If more than 920 participants are randomised in a low-/moderate-severity pandemic then smaller effect sizes may be detectable.

We will compare numbers, age and sex of randomised participants with aggregate summary data of all patients who are admitted to hospital with influenza-like illness during the study period. We will compare baseline characteristics of the randomised arms using appropriate descriptive statistics. Between-group comparisons for primary and secondary outcomes will be conducted using an intention-to-treat (ITT) approach, implemented using appropriate regression models, and with results presented as point estimates, such as a ratio or difference comparing dexamethasone with placebo, with 95% CIs and p-values.
Secondary analyses will include additional adjustment for variables displaying an important imbalance at baseline. We anticipate little, if any, missing primary outcome data and therefore will use ITT without imputation as the main approach, and will investigate the influence of any missing data in sensitivity analyses, including multiple imputation. All analyses will be conducted using Stata version 13 or higher (StataCorp LP, College Station, TX, USA) or MLwiN 2.10 or higher (MLwiN, Centre for Multilevel Modelling, Bristol, UK).

A planned early analysis focused on the primary end points will be performed to provide rapid data to the UK Department of Health prior to the start of the second pandemic wave.

Preplanned subgroup analyses will be conducted for the primary outcome, based on the following baseline factors: (1) duration of symptoms; (2) clinical diagnosis of pneumonia; (3) underlying comorbid illness; and (4) severity of influenza. Outcomes will be reported descriptively by subgroup category and treatment arm, and formally estimated by fitting interaction terms in the regression models. It is recognised that power to detect subgroup effects is likely to be low, and these analyses will be regarded as exploratory and interpreted with due caution.

**Substudy**

In parallel with the ASAP trial, we have set up a mechanistic substudy to be conducted at six pre-selected trial-participating sites. The substudy will collect biological samples from 200 ASAP trial participants in order to determine the interaction of steroid therapy and the host, and to apply this in interpreting the clinical outcomes measured.

All patients recruited into the ASAP trial at substudy sites will be given the opportunity to participate in the substudy. Consent for participation in the substudy will be taken separately to the ASAP trial. Two blood samples and one nasal swab for subsequent transcriptomic and microbiological testing will be obtained from participants at baseline and 48 hours post first dose of ASAP trial medication.
Chapter 2 Results

This trial has not yet been activated. The status of the trial at the end of the set-up phase is reported together with results from patient and public involvement (PPI) consultations.

Patient and public involvement regarding trial consent

Consultations with patients and the public regarding the ASAP trial, and specifically in relation to the consent process, included events with representatives from charitable organisations related to respiratory disorders (Asthma UK, British Lung Foundation, Cystic Fibrosis Trust, British Thoracic Society), PPI representatives of the East Midlands Collaboration for Leadership in Applied Health Research and Care (CLAHRC), a local public library reading group, and members of a town council. In addition, two independent front-line consultants – who were, themselves, patients in the 2009 pandemic – were personally consulted. The majority view from these consultations was a preference for a clear verbal consent process prior to trial enrolment in contrast to a weightier written consent approach (Table 1). Initial opinions from a Research Ethics Committee (REC) also favoured a verbal consent approach; indeed, REC approval for a verbal consent approach was given on 29 October 2013. This approval was subsequently reversed on 11 November 2013, on the grounds of existing legal requirements in relation to controlled trials of investigational medicinal products [Clinical Trial of Investigational Medicinal Product (CTIMPs)]. Following further extensive consultations involving the REC, Health Research Authority (HRA), Medicines and Healthcare products Regulatory Agency (MHRA) and NIHR, during which the results of PPI consultations were made available, eventual REC approval was obtained on 19 February 2014, based on a written consent approach in accordance with current legislation.

Regulatory approvals

This trial has been approved by the UK MHRA (European Union Drug Regulating Authorities Clinical Trial 2013–001051–12) and the South Central – Oxford C REC (13/SC/0436). Global governance checks have been completed in England, Wales and Scotland, enabling sites to issue local UK NHS permissions. The study is International Standard Randomised Controlled Trial Number (ISRCTN) registered, and will be conducted in accordance with the principles of the Declaration of Helsinki, the standards of Good Clinical Practice (as defined by the International Conference on Harmonisation), and UK regulatory and ethical requirements.

Owing to the lengthy hibernation period, MHRA approval was granted on the condition that a substantial amendment is submitted at the time of activation to confirm that there is no change to the risk–benefit analysis of the trial.

The requirement for an annual Development Safety Update Report (DSUR) was waived by the MHRA. In place of this, an annual letter will be sent advising of any changes in risk–benefit analysis of the trial until the trial is activated. Standard DSUR submissions will commence once the trial has been activated.

<table>
<thead>
<tr>
<th>Consent approach</th>
<th>No. of persons</th>
</tr>
</thead>
<tbody>
<tr>
<td>Written consent</td>
<td>2</td>
</tr>
<tr>
<td>Verbal plus deferred written consent</td>
<td>0</td>
</tr>
<tr>
<td>Verbal consent</td>
<td>28*</td>
</tr>
<tr>
<td>Opt-out consent</td>
<td>15*</td>
</tr>
</tbody>
</table>

*a One person felt that verbal consent and opt-out consent had equal merit.*
NHS permissions

Twenty-nine sites have been granted NHS site permission and a further 11 sites are in the process of obtaining local approvals (data as of 22 January 2015). These sites cover a wide geographical area across the UK, including most major cities (Figure 1).

FIGURE 1 Participating sites in the UK (as of 22 January 2015).
The ASAP trial, together with other studies identified as urgent public health research, have been excluded from the NIHR Clinical Research Network (CRN) high-level objective of ‘first patient, first visit within 70 days’, thus enabling sites to grant NHS permission in advance of trial activation.

**Trial activation**

The trial will be activated at the request of NIHR. The decision to activate will be informed by close discussions with Public Health England, trial investigators and the TSC. Recruitment will occur at influenza admission points in all participating sites. It is anticipated that recruitment will be completed by the end of the first wave of the pandemic.
Chapter 3 Discussion

To our knowledge, this is the first multicentre clinical trial that has been set up in order to be placed in hibernation, ready for rapid activation at an unspecified future date. The biggest challenge in setting up this trial has been the uncertainty regarding the timing and severity of a future influenza pandemic. Being prepared for pandemics of different severities was one of the major learning points from research conducted during the 2009 pandemic.31

The trial design is based on the event of a high-severity pandemic, this being the default position at the start of a pandemic when the severity of a pandemic may not yet be apparent. To allow for a less severe pandemic, we have included flexibility within the trial conduct and analysis.

Choice of intervention

Different corticosteroids have been, and are currently being, tested in the context of acute severe infections and sepsis. The most commonly used oral preparations are dexamethasone and prednisolone. Compared with prednisolone, dexamethasone has (1) minimal mineralocorticoid activity and does not affect sodium and water balance, thus avoiding potential problems with fluid retention, which are not uncommon in severe viral pneumonitis, and (2) a comparatively long biological half-life, potentially offering protection against late failures resulting from rebound inflammation.17

The oral liquid preparation will enable the vast majority of eligible participants to receive the intervention except those who are either strictly ‘nil by mouth’ or who are unable to swallow. For some of these participants, administration via an enteral feeding tube will be possible. This approach is similar to the manner in which oseltamivir (Tamiflu®, Roche) was administrated during the 2009 pandemic [no intravenous (i.v.) formulation licensed at the time], when only a small proportion (<3%) of patients in intensive care received ‘off-licence’ i.v. antiviral therapy.32

The oral absorption of corticosteroids in patients who are admitted to hospital with severe respiratory illness or sepsis might potentially be impaired as a result of delayed gastric emptying or altered first-pass metabolism.33 In an open-label randomised trial of i.v. dexamethasone compared with oral dexamethasone in patients who were admitted to hospital with community-acquired pneumonia, oral bioavailability was found to be good (81%) and comparable with results from studies performed in healthy individuals.34 No equivalent studies have been performed in critically ill patients and it remains possible that the very sickest patients will experience impaired oral absorption of dexamethasone. These patients are likely to be managed on an ICU (meeting one of the primary end points) and to represent a small proportion of the study cohort. Overall, the potential benefit of providing an i.v. preparation, with matching placebo, for use in selected trial participants, was considered to be outweighed by the risks this would pose to the practical and successful conduct of the trial in the context of a pandemic.

Evidence from existing trials of low-dose corticosteroids have not identified an increased risk of gastrointestinal complications, therefore no additional requirement for gastroprotection is required in this trial. The coherence of these decisions in relation to the trial intervention will continue to be reviewed during the hibernation phase of the trial as results from ongoing studies become available.25,35

The following discussion highlights the hurdles encountered in setting up this trial and the considered threats to the successful conduct of this trial during a pandemic. Other investigators planning to set up similar ‘off-the-shelf’ clinical trials in response to public health crises may encounter similar challenges.
Hurdles

Pressure on NHS resources
In the event of a high-severity pandemic, the NHS will be under considerable pressure to continue to deliver high-quality care to all patients. Under such circumstances, any additional non-essential work is likely to be deferred. This applies at the individual level as well.

The successful conduct of pragmatic acute care multicentre trials is challenging at the best of times. The need for any research-specific measurements requiring additional patient involvement or follow-up increases trial complexity and hence the burden of research, with potentially negative impacts on trial conduct. These challenges are magnified during a pandemic. To reduce any extra work related to participation in the ASAP trial, trial processes and procedures were minimised to the bare essentials. No additional investigations or measurements are necessary for the ASAP trial; data required for all major outcome measures will be captured from routine medical data sources.

Co-enrolment of patients
At the time of reporting, there were at least four pandemic studies that were planning to recruit patients with influenza infection in the UK hospital setting: two are part of the NIHR pandemic portfolio. Of these four studies, the only clinical intervention trial is the ASAP trial; the others are observational cohort or biological sampling studies.

The chief investigators of these trials have agreed that there is no bar to co-enrolment of patients to the ASAP trial and another study. However, other pandemic studies may be set up in future, which may compete for the same patient pool. Even if a principle of co-enrolment could be observed, it may not be acceptable for patients to be approached to participate in multiple studies simultaneously.

An expansion of pandemic studies in future will likely require some degree of prioritisation of the delivery of such research. For instance, although patients entered into the ASAP trial will not be eligible to participate into another trial simultaneously, if a patient is admitted to intensive care and hence meets one of the primary composite end points for a high-severity pandemic, it may be reasonable to consider trial exit for that patient and subsequent enrolment in another trial. Such a decision would depend on a number of factors, including whether or not the severity of the pandemic had already been definitively declared, as this would affect the primary end point for the ASAP trial, the potential public health impact of different trials, the likelihood of completion of a trial, possible biological interactions and patient wishes.

Whether such prioritisation should be left to local sites or co-ordinated more centrally warrants exploration as part of pandemic preparedness planning. The NIHR has established a CRN Urgent Public Health Group to help ensure that urgent public health studies can be set up and delivered quickly and effectively. Commercial studies may apply for approval as relevant to the urgent public health risk. However, co-enrolment involving commercial studies, whether observational or interventional, may not meet with approval by industrial partners. The impact of allowing or disallowing co-enrolment should be carefully considered at the time of approval of studies for priority status within the CRN urgent public health research framework.

Engagement of sites
Maintaining the interest and focus of sites through the set-up process has required constant effort. Understandably, because of the perception that the ASAP trial may not be activated for an undefined period of years, there is less impetus to work on this trial compared with that of other trials that have more imminent datelines.
Establishing dialogue with a core team of local investigators at each site, and enabling them to better anticipate the potential barriers to conducting a trial during a pandemic, has coincided with the role of ‘pandemic champions’ promoted by the Infectious Diseases and Microbiology Specialty Group to the NIHR CRNs.

The support of the Specialty Group has been invaluable not only for establishing links with interested sites, but also in raising national awareness of the trial. To ensure the delivery of pandemic research, the Specialty Group has prepared a suite of documents around urgent public health research and how it will support delivery. The ASAP trial is a recognised urgent public health study; this has provided valuable reassurance to sites of their ability to conduct clinical research during such an emergency.

Site visits during the hibernation phase may be required to maintain study awareness and confirm pandemic preparedness. Including the delivery of NIHR-funded pandemic studies in individual NHS trust pandemic plans is a further desirable step towards integrating pandemic research into service delivery.

**Site selection**

Although it is anticipated that any future influenza pandemic would affect the whole of the UK, different regions may be more or less severely affected. The location and distribution of pandemic ‘hot spots’ is unpredictable.1

The 40 sites participating in the ASAP trial are well distributed across the UK. Sites that do not experience much influenza activity during the first pandemic wave may not be activated. In addition, we have provided for a ‘flying squad’ of research nurses to respond to ‘hot spots’, in support of local research teams.

The occurrence of ‘hot spots’ increases the probability of patient transfers from one hospital to another to maintain patient flow and bed capacity. It is not possible to predict which hospitals might be involved in receiving patients. We are currently working on a generic site-specific information form for continuing care sites, to enable non-recruiting sites to continue IMP administration and data collection should a trial participant be transferred in.

**Supply of Investigational Medicinal Product**

A high-severity pandemic would not only place the NHS under considerable pressure, but also would affect other businesses, particularly through staff sickness. To improve resilience in the supply of IMP and placebo to participating trial sites, contracts with multiple manufacturing and distribution units have been established.

**Training of local investigators**

Local health-care workers (HCWs) will need to be actively involved in the identification of patients who are eligible for the ASAP trial and taking patient consent. Informing and training large numbers of local HCWs with regards to the ASAP trial in advance of a pandemic (i.e. in the interpandemic period) is unsustainable. More junior HCWs, in particular, will be likely to move on before the trial is activated and the remaining HCWs would require refresher training prior to trial activation.

A suite of trial-specific training material has been prepared jointly with Good Clinical Practice trainers, in consultation with the NIHR. This material has been designed to be easy to read and suitable for rapid dissemination in the preactivation phase to local HCWs who will be involved in the trial.

**Command and control**

During the severe acute respiratory syndrome outbreak in 2003, good command and control was identified as a major factor in the management of patients and hospital resources.40 At the same time, undue reliance on any single individual or process is to be avoided.
The Nottingham Clinical Trials Unit (NCTU) has begun development of an internal pandemic plan to increase its resilience in the event of a pandemic, with special emphasis on the successful delivery of the ASAP trial. This includes the potential move of the trial team to an off-hospital site, away from clinical areas where patients with influenza will be managed. Online resources are being developed, both as a repository of information and a means for rapid updates to participating sites.

**Threats**

**Changes during hibernation**
The timing of a future pandemic is unpredictable. The ASAP trial has been set up with a hibernation phase of up to 10 years. There will inevitably be local and national infrastructural, policy and staff changes in this time. Maintaining trial readiness throughout these changes will require active management. As an example, in anticipation of a move overseas to take up a research directorship post, one of the trial co-investigators (SG) has already engaged another investigator (D Wootton) to take over responsibilities related to the ASAP trial. Such future-proofing strategies require forethought and long-term commitment.

Unforeseen changes that might undermine the integrity of the trial as it is currently set up may yet arise. Advances in the management of severe acute respiratory illnesses and the potential introduction of new therapies for severe influenza in particular may prompt alterations to the trial during the hibernation phase. An adaptive trial design to enable other treatment arms to be added to the ASAP trial is one consideration; any additional resources required may be justified in view of potential gains.

**Lack of research staff**
Current planning assumptions are that up to 50% of staff may be affected over the period of the pandemic, either directly by the illness or by caring responsibilities, thereby creating potential pressures on the response. In addition to absenteeism, research staff may also be diverted to front-line clinical work. Lack of staff was identified as the main reason for poor recruitment in a pandemic trial that had to be terminated prior to completion during the 2009 pandemic. To mitigate against this, we have designed the study to minimise the research sources required from sites for the conduct of this study; for instance, data collection and the Case Report Form have been designed with completion by trained administrative staff, and not necessarily by research nurses, in mind. Nevertheless, a minimum core team of local research investigators will be required at each participating site.

Employment of new research staff to support the conduct of the ASAP trial is unlikely to be feasible in view of the short time scale from recognition of a pandemic to trial activation. Redeployment of research staff from other areas of research will be required. The Comprehensive Local Research Network (CLRN) have prioritised the NIHR pandemic portfolio of studies. However, no standing agreement is in place between NIHR and other funding bodies, such as the Medical Research Council or Wellcome Trust.

High-level cross-organisational agreement is needed. Discussions held during the interpandemic period to agree on principles for prioritisation will help facilitate the more detailed discussions that will be required at the onset of a pandemic. Ultimately, the successful delivery of this trial will depend crucially on the timely and sufficient support by CLRN units at all participating sites during the pandemic.

**Written informed consent**
The process of taking written informed consent for a research study can potentially lead to delays in patient care with clinical consequences. This is most likely to occur when research is conducted in the context of emergency care. Some patients with severe influenza will present to hospital in a state of emergency; the mean time from hospital admission to ICU transfer was 2 days during the 2009 pandemic. In addition to individuals who require emergency care, a state of emergency will also prevail across the management of all patients because of the pressures on the NHS, particularly in the context of a high-severity pandemic.
The current legal requirement for a CTIMP, such as the ASAP trial, is for written informed consent, outside the waiver for emergency research.44 This waiver applies only to individuals who require emergency care and does not include situations when the health service is in a state of emergency.

The consent approach for the ASAP trial (written informed consent) adheres to existing legal and regulatory standards for a CTIMP. However, as identified during PPI consultations, this may place it at odds with the opinions of patients and the public during a pandemic. Whether or not this will adversely impact on recruitment rates or patient management remains to be determined.

Public engagement: social media
The public’s perception of pandemics is variable.45,46 Experience of the 2009 pandemic, which was less severe than initially portrayed, may alter how news regarding a future pandemic is received. The ASAP trial might receive wide media exposure during a pandemic and the tone of such media coverage could impact on the conduct of the trial. A public relations strategy for the NIHR pandemic portfolio of studies, including the ASAP trial, will be necessary from the time of activation.

A model for ‘off-the-shelf’ trials in public health emergencies
An influenza pandemic constitutes a public health emergency, as do bioterrorist attacks, natural disasters (such as severe flooding) and major industrial accidents leading to toxic exposures, such as from the Fukushima nuclear reactor in Japan. Awareness of the need to be better prepared to resolve important research questions in the context of a public health emergency has been growing over the last decade.47 Randomised trials provide the best evidence to guide clinical practice and health policy. However, public health emergencies are, by nature, unpredictable in their timing and scale. In addition, they are typically of limited duration. These aspects pose considerable challenges to the design, set-up and execution of randomised trials.

Lessons learnt from the set-up of this study may benefit the design of other ‘off-the-shelf’ trials in future.
Chapter 4 Conclusion

Advance set-up of a pandemic trial with full regulatory approvals in place enables the resolution of many issues at an early stage outside the ‘heat’ of a pandemic. Regular attention to trial readiness during the hibernation phase will be required. This study serves as a model for the development of other ‘off-the-shelf’ trials as part of preparedness planning for public health emergencies.
Acknowledgements

We thank the team at the NCTU for all of their hard work in setting up this trial. We also thank the East Midlands Local CRN, members of the TSC and Data Monitoring Committee, Maria Koufali and staff of Research & Innovation, Nottingham University Hospitals NHS Trust, Local CRNs for participating sites, Sarah Cooper at the National Coordinating Centre of the NIHR CRN, and all participating NHS sites for their ongoing help and support. Special thanks are extended to Rosemont Pharmaceuticals Ltd for its co-operation, and to the many volunteers who contributed to the design of this trial, including representatives from the British Thoracic Society Public Liaison Committee, East Midlands CLAHRC, Stapleford Town Council and the Arnold Library, Nottingham.

Contributions of authors

Wei Shen Lim and Jonathan Nguyen-Van-Tam conceived the study.

Wei Shen Lim, Clare Brittain, Lelia Duley, Alan Montgomery and Diane Whitham managed the set-up of the study.

Stephen Gordon, Robert Read and Dan Wootton led the design of the substudy.

Wei Shen Lim drafted the report.

Sheila Edwards helped in organising PPI involvement for the study.

All authors contributed to the design of the study and the writing the report. The final draft was approved by all authors.
References


45. Rubin G, Potts H, Michie S. The impact of communications about swine flu (influenza A H1N1v) on public responses to the outbreak: results from 36 national telephone surveys in the UK. Health Technology Assessment 2010; **14**(34). http://dx.doi.org/10.3310/hta14340-03

Appendix 1 Protocol

Early low dose steroids for adults admitted to hospital with influenza-like illness during a pandemic: a randomised placebo controlled trial

CLINICAL TRIAL PROTOCOL


Internal Reference No: 11RM013
Ethics Ref: 13/SC/0436
EudraCT Number: 2013-001051-12
ISRCTN: ISRCTN72331452

Sponsor: Nottingham University Hospitals NHS Trust
Co-ordinating Centre: Nottingham Clinical Trials Unit (NCTU)
Chief Investigator: Dr Wei Shen Lim
Consultant Respiratory Physician
Nottingham University Hospitals NHS Trust
Funded by: NIHR Programme NETSCC Pandemic Flu/
Personal Award Reference Number: 11/46/14
Countries of Recruitment: United Kingdom
PROTOCOL SIGNATURE PAGE

ASAP Protocol Final Version 3.0 dated 07-Oct-2014

This protocol has been approved by:

<table>
<thead>
<tr>
<th>Name and role</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Wei Shen Lim</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief Investigator</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr Dan Wootton</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sub-study Investigator</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr Maria Koufali,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CONTACT DETAILS

Chief Investigator:  
Dr Wei Shen Lim  
Consultant Respiratory Physician  
Nottingham University Hospitals NHS Trust  
City Campus  
Hucknall Road  
Nottingham  
NG5 1PB  
✉️ weishen.lim@nuh.nhs.uk  
📞 0115 969 1169 ext 59347

Co-investigators:  
Professor Jonathan Nguyen-Van-Tam  
Professor of Public Health  
Division of Epidemiology and Public Health  
University of Nottingham

Professor Robert Read  
Professor of Infectious Disease  
Faculty of Medicine  
University of Southampton

Professor Stephen Gordon  
Professor of Tropical Respiratory Medicine  
School of Tropical Medicine  
Liverpool School of Tropical Medicine

Professor Mark Woodhead  
Consultant Respiratory Physician  
Respiratory Medicine  
Manchester Royal Infirmary

Professor Leila Duley  
Professor of Clinical Trials Research  
Director, Nottingham Clinical Trials Units  
University of Nottingham

Diane Whitham  
Research Manager  
Deputy Director, Nottingham Clinical Trials Unit  
University of Nottingham

Mrs Sheila Edwards  
Chief Executive, British Thoracic Society

Professor David Whynes  
Professor Health Economics  
School of Economics  
University of Nottingham

Professor Alan Montgomery  
Professor of Medical Statistics and Clinical Trials  
Deputy Director, Nottingham Clinical Trials Unit  
University of Nottingham
Sub-study investigators:  
Dr Dan Wootton  
Clinical Lecturer in Respiratory Medicine  
Department of Clinical Infection Microbiology and Immunology  
Institute of Infection and Global Health  
Ronal Ross Building  
8 West Derby Street  
Liverpool  
L69 7BE  
✉️ d.wootton@liverpool.ac.uk  
📞 07979 515929

Professor Stephen Gordon  
Professor of Tropical Respiratory Medicine  
Liverpool School of Tropical Medicine  
Pembroke Place  
Liverpool  
L3 5QA  
✉️ sbgordon@liverpool.ac.uk  
📞 0151 705 3169

Professor Robert Charles Read  
Faculty of Medicine  
University of Southampton  
Southampton General Hospital  
Mailpoint 810  
South Academic Block  
Tremona Road  
Southampton  
SO16 6YD  
✉️ r.c.read@soton.ac.uk  
📞 02380 794271

Trial statistician:  
Professor Alan Montgomery  
Professor of Medical Statistics and Clinical Trials  
Deputy Director, Nottingham Clinical Trials Unit  
University of Nottingham  
✉️ alan.montgomery@nottingham.ac.uk  
📞 0115 884 4953

Trial Manager:  
Clare Brittain  
Nottingham Clinical Trials Unit  
Nottingham Health Science Partners  
Floor C, South Block  
Queens Medical Centre  
Nottingham  
NG7 2UH  
✉️ asap@nottingham.ac.uk  
📞 0115 884 4952
TABLE OF CONTENTS

1 AMENDMENT HISTORY .................................................................................................................. 7
2 SYNOPSIS ..................................................................................................................................... 8
3 ABBREVIATIONS .......................................................................................................................... 10
4 BACKGROUND AND RATIONALE ............................................................................................. 11
5 OBJECTIVES .................................................................................................................................. 13
  5.1 Primary Objective ..................................................................................................................... 13
  5.2 Secondary Objectives ............................................................................................................... 13
6 TRIAL DESIGN ............................................................................................................................. 13
  6.1 Summary of Trial Design ........................................................................................................ 13
  6.2 Outcome measures .................................................................................................................. 17
    6.2.1 Primary outcome ............................................................................................................... 17
    6.2.2 Secondary outcomes ....................................................................................................... 17
  6.3 Trial Participants ..................................................................................................................... 17
    6.3.1 Overall Description of Trial Participants ....................................................................... 17
    6.3.2 Inclusion Criteria ............................................................................................................ 17
    6.3.3 Exclusion Criteria ............................................................................................................ 17
  6.4 Study Procedures .................................................................................................................... 18
    6.4.1 Screening and Eligibility Assessment .............................................................................. 18
    6.4.2 Consent .......................................................................................................................... 18
    6.4.3 Randomisation ................................................................................................................ 21
    6.4.4 Collection of hospital admission data ............................................................................ 21
    6.4.5 Subsequent assessments ................................................................................................. 22
    6.4.6 Maintenance of randomisation codes and procedures for unblinding ......................... 22
  6.5 Definition of End of Trial ....................................................................................................... 22
  6.6 Discontinuation of trial treatment or withdrawal of participants ......................................... 23
    6.6.1 Discontinuation of trial treatment .................................................................................. 23
    6.6.2 Withdrawal from the trial ............................................................................................... 23
  6.7 Source Data ............................................................................................................................ 23
7 TREATMENT OF TRIAL PARTICIPANTS .................................................................................. 23
  7.1 Description and manufacture of trial treatment ..................................................................... 23
    7.1.1 Dosage .......................................................................................................................... 24
    7.1.2 Packaging and Labelling ............................................................................................... 24
  7.2 Storage of Trial Treatment ..................................................................................................... 24
  7.3 Compliance with Trial Treatment .......................................................................................... 24
  7.4 Accountability of the Trial Treatment .................................................................................... 25
  7.5 Concomitant Medication ...................................................................................................... 25
8 SAFETY REPORTING .................................................................................................................... 25
  8.1 Definitions ............................................................................................................................... 26
    8.1.1 Serious Adverse Event (SAE) ....................................................................................... 26
    8.1.2 Serious Adverse Reaction (SAR) ................................................................................... 26
8.1.3 Expected Serious Adverse Reactions (Expected SAR) ........................................ 26
8.1.4 Suspected Unexpected Serious Adverse Reactions (SUSARs) ........................... 26
8.2 Reporting procedure ................................................................................................... 26

9 STATISTICAL CONSIDERATIONS ................................................................................... 28
9.1 Description of Statistical Methods ............................................................................... 28
9.2 The Number of Participants ......................................................................................... 29
9.3 Interim Analyses .......................................................................................................... 29
9.4 Procedure for accounting for missing, unused, and spurious data............................. 30

10 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS .................................................. 30
11 QUALITY CONTROL AND QUALITY ASSURANCE PROCEDURES ..................... 30

12 ETHICS ........................................................................................................................ .. 30
12.1 Declaration of Helsinki ................................................................................................. 30
12.2 ICH Guidelines for Good Clinical Practice ................................................................. 31
12.3 Approvals .................................................................................................................... 31
12.4 Participant Confidentiality ............................................................................................ 31
12.5 Other Ethical Considerations ....................................................................................... 31

13 DATA HANDLING AND RECORD KEEPING .............................................................. 31
14 FINANCING AND INSURANCE ..................................................................................... 31
15 PUBLICATION POLICY ................................................................................................. 31
16 HEALTH ECONOMICS .................................................................................................. 32
17 REFERENCES ............................................................................................................... 32

Appendix A – Trial Flow Chart .......................................................................................... 34
Appendix B – Mechanistic sub-study: determining the interaction of steroid therapy and the host ................................................................................................................................................ 35
# 1 AMENDMENT HISTORY

<table>
<thead>
<tr>
<th>Amendment No.</th>
<th>Protocol Version No.</th>
<th>Date issued</th>
<th>Author(s) of changes</th>
<th>Details of Changes made</th>
</tr>
</thead>
</table>
| Protocol amendment 1  
(Amendment ref. SA02) | 1.0                   | 23-Oct-13   | Dr Wei Shen Lim      | Update to consent section; replacement of initial verbal consent with use of a single page combined patient information sheet and consent form at the point of hospital admission. |
| Protocol Amendment 2  
(Amendment ref: SA08) | 2.0                   | 11-Feb-14   | Dr Wei Shen Lim      | Addition of Appendix B  
(mechanistic sub-study)  
Correction made to section 6.3.3 that trial treatment will be discontinued if participant is later found to meet exclusion criteria.  
Added that an appropriately trained research nurse may take written consent.  
Added that treatment pack will also contain a spoon for drug administration and a wristband for trial participants  
Minor spelling corrections/administrative changes. |
2 SYNOPSIS

**Study Title**
Early low dose steroids for adults admitted to hospital with influenza-like illness during a pandemic: a randomised placebo-controlled trial

**Internal ref. no.**
11RM013

**Clinical Phase**
Phase III

**Trial Design**
Pragmatic multi-centre double-blind randomised trial

**Trial Participants**
Adults (≥ 16 years old) hospitalised with an influenza-like illness during a pandemic.

**Planned Sample Size**
2200 patients.
The planned sample size is based on the range of possible scenarios that might be encountered during a pandemic. With 2200 patients, the study will have 90% power to detect a 15% relative reduction in the primary outcome (admission to intensive care or death).

**Follow-up duration**
Patients will be asked to complete a follow-up questionnaire 30 days after hospital discharge. Completion of the questionnaire is not required for patients hospitalised ≥60 days. Patient outcome information will be collected from hospital-based system records for these patients.

**Planned Trial Period**
The trial is unique as it will be set up pre-pandemic. Once set-up is complete and all the required approvals have been obtained, the trial will be placed into ‘hibernation’.

After the initial set-up, there will be 3 distinct phases to the trial.

1) **Hibernation phase**
During hibernation, regular review (at least annually) of trial procedures and sites will ensure that the trial is maintained in a state in which it can be readily activated to start recruitment in the event of a pandemic.

2) **Pre-activation phase**
When the National Institute for Health Research (NIHR) decide to activate the trial, a pre-activation phase of four to six weeks will begin immediately. This will include final review of trial procedures, trial drug production and distribution, production and distribution of trial materials and a check of site readiness prior to beginning recruitment.

3) **Activation phase**
During activation, patients will be recruited into the trial. Recruitment is planned to be completed within the first pandemic wave, typically of six weeks duration. This phase also includes data collection and follow-up.

**Primary Objective**
To determine whether during a pandemic, for adults (≥16 years) hospitalised with an influenza-like illness, a 5-day course of dexamethasone started within 24 hours of admission to hospital, in addition to standard care, is associated with a lower risk of death or admission to intensive care compared to placebo.

**Secondary Objectives**
To determine whether dexamethasone given in addition to standard care is associated with a reduction in the length of hospital stay, the frequency of hospital readmission and/or the frequency of GP consultations after discharge compared to placebo. If dexamethasone is effective, the study will also evaluate its cost-effectiveness.
### Primary Endpoint

Admission to intensive care unit or death, within 30 days of hospital admission

### Secondary Endpoints

1. Length of stay in intensive care unit
2. Readmission within 30 days of hospital discharge
3. GP consultations within 30 days of hospital discharge
4. Length of stay in hospital
5. Death within 30 days of admission to hospital
6. Admission to intensive care unit within 30 days of admission to hospital

The full statistical analysis plan for this trial includes the flexibility to allow for pandemics of different severity.

### Investigational Medicinal Product

Dexamethasone, given as adjuvant therapy in addition to standard care.

- **Form:** Liquid
- **Dose:** 6 mg once daily for 5 days from randomisation
- **Route:** Oral (or enteral through nasogastric tube)
3 ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse event</td>
</tr>
<tr>
<td>ASAP</td>
<td>Adjuvant Steroids in Adults with Pandemic Influenza</td>
</tr>
<tr>
<td>CI</td>
<td>Chief Investigator</td>
</tr>
<tr>
<td>COPD</td>
<td>Chronic Obstructive Pulmonary Disease</td>
</tr>
<tr>
<td>CFR</td>
<td>Case Fatality Ratio</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Report Form</td>
</tr>
<tr>
<td>DMC</td>
<td>Data Monitoring Committee</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>GP</td>
<td>General Practitioner</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference of Harmonisation</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive Care Unit</td>
</tr>
<tr>
<td>IMP</td>
<td>Investigational Medicinal Product</td>
</tr>
<tr>
<td>ITT</td>
<td>Intention-to-treat</td>
</tr>
<tr>
<td>LOS</td>
<td>Length of stay in hospital</td>
</tr>
<tr>
<td>MHRA</td>
<td>Medicines and Healthcare products Regulatory Agency</td>
</tr>
<tr>
<td>NCTU</td>
<td>Nottingham Clinical Trials Unit</td>
</tr>
<tr>
<td>NETSCC</td>
<td>NIHR Evaluation, Trials and Studies Coordinating Centre</td>
</tr>
<tr>
<td>NHS</td>
<td>National Health Service</td>
</tr>
<tr>
<td>NIHR</td>
<td>National Institute for Health Research</td>
</tr>
<tr>
<td>PHE</td>
<td>Public Health England</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>NHS Trust R&amp;D Department</td>
</tr>
<tr>
<td>REC</td>
<td>Research Ethics Committee</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event</td>
</tr>
<tr>
<td>SAR</td>
<td>Serious Adverse Reaction</td>
</tr>
<tr>
<td>SOP</td>
<td>Standard Operating Procedure</td>
</tr>
<tr>
<td>SPC</td>
<td>Summary of Product Characteristics</td>
</tr>
<tr>
<td>SUSAR</td>
<td>Suspected Unexpected Serious Adverse Reactions</td>
</tr>
<tr>
<td>TMG</td>
<td>Trial Management Group</td>
</tr>
<tr>
<td>TSC</td>
<td>Trial Steering Committee</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organisation</td>
</tr>
</tbody>
</table>
4 BACKGROUND AND RATIONALE

Pandemic influenza occurs when a new influenza A virus strain emerges which is antigenically distinct from circulating influenza strains, and which is able to infect humans, spreading efficiently from person to person causing significant clinical illness in a high proportion of those infected. Since the beginning of the 20th century, there have been 4 influenza pandemics of varying severity. The devastating 1918 pandemic (‘Spanish flu’) caused by influenza A/H1N1 resulted in 20 to 50 million deaths worldwide, representing a case-fatality ratio (CFR) of 2 – 3%. Subsequent pandemics in 1957 (H2N2) and 1968 (H3N2) resulted in approximately 1 to 4 million deaths worldwide; CFR 0.1 to 0.4%. In contrast, the 2009 pandemic (H1N1) was much less severe. It affected mainly people aged below 55 years of age, and had a low case-fatality ratio (0.025%) in the UK similar to that of recent seasonal influenza viruses [1]. The timing and severity of future influenza pandemics remains unpredictable. There are currently no markers that will predict the pathogenicity or spread of a potential pandemic strain in the human population. Therefore, any plans for a future pandemic need to be flexible and take account of different possible scenarios from mild to severe.

Presentation and prognosis

Influenza virus infection is associated with a wide spectrum of illness, from no symptoms to pneumonia and death. During a pandemic, most people are expected to experience a minor influenza-like illness characterized by fever and cough typically lasting 7 to 10 days. Nevertheless, the UK Pandemic Influenza Preparedness Strategy 2011 recommends that for pandemic planning an estimated 1-4% of symptomatic patients should be expected to require hospital care.[2] Patients may be admitted to hospital either because of influenza-related exacerbations of underlying co-existing illnesses such as chronic obstructive pulmonary disease (COPD), or due to complications of influenza infection such as pneumonia.

Following hospital admission, some patients deteriorate rapidly (within 24 hours) and require intensive care unit (ICU) level support for respiratory failure. The proportion who might require ICU support in a pandemic is difficult to predict, and a range of 15% to 25% of hospitalized patients has been suggested. In a severe pandemic, resource limitations will probably define the upper limit. In the 2009 H1N1 pandemic (a low severity pandemic), 17% of hospitalized patients were admitted to Level 2 or Level 3 care.[3] the median time from symptom onset to ICU admission was 6 days, and from hospital admission to ICU admission was 2 days.

A figure of up to 200,000 additional deaths across the UK over a 15 week period has been proposed for planning purposes in the UK Pandemic Influenza Preparedness Strategy 2011. In the ‘low severity’ 2009 pandemic, 7% of hospitalized patients with confirmed H1N1 influenza infection died [3].

Current standard therapy for influenza infection

In the management of patients admitted to hospital with influenza infection during a pandemic, current Clinical Management Guidelines recommend that all adults receive appropriate supportive care, including fluid replacement and oxygen supplementation, and antiviral therapy [4]. In addition, antibiotic therapy is recommended for all hospitalised adults except previously well adults with only influenza-related acute bronchitis.

Corticosteroids in influenza

During the early phase of illness, influenza A virus infection induces inflammatory (e.g. IL-6, IL-8) and T-helper type 1 (Th1) cell immune responses (e.g. IFN-induced protein 10 (IP-10), monokine induced by IFN-gamma (MIG), correlating with clinical illness [5]. Hypercytokinaemia is also recognized in patients with H5N1 influenza infection (e.g. IL-6,IL-10, MIG) with the highest levels found in patients who subsequently die [6]. Similar changes have been observed in patients with 2009 pandemic H1N1 infection [7]. Such inflammatory cytokines may suppress the hypothalamic-pituitary-adrenal axis resulting in relative adrenal insufficiency or compete with intracellular glucocorticoid receptor function, resulting in peripheral tissue steroid resistance [8]. Corticosteroids in low doses (e.g. hydrocortisone ≤ 300mg per day or dexamethasone ≤ 11.25 mg/day) downregulates proinflammatory cytokine transcription and has been shown to improve innate immunity in patients with septic shock [9, 10].
APPENDIX 1

There are no completed randomised trials of the use of corticosteroids in patients with pandemic, avian or seasonal influenza infection. Corticosteroid use in influenza is widespread, non-systematic and marked by controversy [11-14]. During the 2009 pandemic, corticosteroid use in critically ill patients with H1N1 influenza was identified in 83 (30%) of 208 patients in a French registry [15], 107 (44%) of 245 patients in a South Korean cohort study and 126 (57%) of 220 patients in the European Society of Intensive Care Medicine H1N1 registry [16]. The heterogeneity of these cohort studies and non-randomised study designs preclude any firm conclusions regarding the risks or benefits of corticosteroids in influenza. In these cohort studies of critically ill patients with 2009 H1N1 pandemic influenza, the association of corticosteroids with mortality varied from a decrease in mortality, to no effect on mortality or an increase in mortality [13, 15-17]. Some cohort studies observed an association of corticosteroids with an increase in hospital acquired pneumonia, including fungal pneumonia [13, 15-17]. One cohort study of 83 hospitalised patients, of whom 17 received parenteral corticosteroids during the first 72 hours of illness, observed an increased risk of critical illness in corticosteroid treated patients (RR 1.8, 95% CI 1.2 to 2.8) [18]. Although multivariate analyses were employed in most of these studies, bias arising from confounding by indication (corticosteroids prescribed in the sickest patients as a ‘treatment of last resort’) cannot be fully discounted.

The World Health Organisation (WHO) Clinical management of human infection with pandemic (H1N1) 2009 : revised guidance[19] recommended that systemic corticosteroids should not be given in severe influenza unless indicated for other reasons or as part of an approved research protocol. A Cochrane meta-analysis of studies of corticosteroids in influenza is on-going and will inform the yearly review of the Trial Protocol during the hibernation phase.

A) Effectiveness of corticosteroids in pneumonia. Trials of corticosteroids in patients hospitalised with community acquired pneumonia have reported varying results. Meijvis et al (n=304) observed a significant reduction in median length of stay together with greater declines in C-reactive protein (CRP) and interleukin-6 levels in the treatment arm (dexamethasone 5 mg for 4 days) [20]. In contrast, Snijders et al (n=213) did not detect a significant difference in clinical cure rate at Day 7 despite a faster rate of defervescence and decline in CRP levels in the treatment arm (prednisolone 40 mg for 7 days) [21]. An earlier small, inadequately powered, open-labelled trial by Mikami et al (n=31), did not detect any statistical difference in length of stay between groups [22].

In patients with severe community acquired pneumonia admitted to intensive care (ICU) [23], Confalonieri et al found hydrocortisone was significantly associated with improved oxygenation and a reduction in multiple organ dysfunction score on Day 8, and a reduction in delayed septic shock. This trial was stopped early (n=46) per protocol after the upper stopping boundary for improvement in oxygenation (PaO2/FiO2 ratio) was achieved. A significant reduction in length of stay (13 v 21 days, p = 0.03) and mortality (0% v 30%, p=0.009) was also observed.

B) Effectiveness of corticosteroids in sepsis. A systematic review of trials examining the benefit of corticosteroids in severe sepsis and septic shock in adults identified [24] 12 randomized or quasi randomised trials (n=1228) comparing low dose corticosteroids (hydrocortisone ≤ 300mg per day (equivalent to dexamethasone 11.25 ≤ mg/day)) for ≥ 5 days with placebo or supportive care. The 28-day mortality for treated versus control patients was 37.5% versus 44.1% (RR 0.84, 95% CI 0.72 to 0.97). These results included the study by Confalonieri et al, 2005. Similar results were observed when this trial was removed from the analysis (RR 0.87, 95% CI 0.77 to 0.98). These studies of corticosteroids in sepsis differ from the studies in community acquired pneumonia in the timing of corticosteroid intervention; occurring later in the disease process when severe sepsis or septic shock was evident.

Potential harm of corticosteroids

A systematic review of corticosteroid trials in severe sepsis and septic shock did not identify any increased risk of gastroduodenal bleeding, superinfection or neuromuscular weakness. An association with an increased risk of hyperglycaemia (RR 1.16, 95% CI 1.07 to 1.25) and hypernatraemia (RR 1.61, 95% CI 1.26 to 2.06) was noted.

Of trials in community acquired pneumonia, Meijvis et al observed that hyperglycaemia was commoner in the treatment group, while Snijders et al noted that the risk of hyperglycaemia requiring additional therapy was non-significantly higher in the treatment group (2.3% of 104 v 0.9% of 109, p=0.27) [20, 21]. Snijders et al observed an increase in late failures in corticosteroid treated patients compared to controls; described as the need for an additional course of antibiotics, need for another or prolonged course of prednisolone or development of a parapneumonic effusion necessitating additional therapy. Rebound inflammation due to the withdrawal of corticosteroids may explain this finding. In contrast, Meijvis et al, did
not observe any differences in late failure. This may relate to relative differences between the half-lives of the different corticosteroids tested (prednisolone vs dexamethasone).

A meta-analysis of trials investigating the use of corticosteroids in acute bacterial meningitis observed that participants treated with corticosteroids had an increase in recurrent fever (RR 1.27, 95% CI 1.09 to 1.47) [25]. The rate of persistent fever was lower in the corticosteroids treated patients (RR 0.29, 95% CI 0.12 to 0.70) while other complications (including gastrointestinal haemorrhage) occurred in similar proportions of treatment and control groups.

Choice of trial intervention

Dexamethasone, compared to prednisolone, has a) minimal mineralocorticoid activity and does not affect sodium and water balance, thus avoiding potential problems with fluid retention which are not uncommon in severe viral pneumonitis, and b) a comparatively long biological half-life of 36 to 54 hours; thus extending the pharmacological effects of a 5 day treatment course to over 11 days and potentially offering protection against late failures due to rebound inflammation.

Description of study intervention

The study intervention is dexamethasone administered as an oral liquid preparation, within 24 hours of hospital admission. The regimen is 6 mg once daily for five days. Dexamethasone 6 mg is equivalent to prednisolone 40 mg or hydrocortisone 160 mg.

The oral liquid preparation will enable the vast majority of eligible participants to receive the intervention except those who are either strictly ‘nil by mouth’ or are unable to swallow. For some of these participants, administration via an enteral feeding tube will be possible. This approach is similar to the manner in which oseltamivir (no IV formulation licensed at the time) was administered during the 2009 pandemic, when only a small proportion (less than 3%[26], [27]) of patients in intensive care received ‘off-licence’ intravenous antiviral therapy.

5 OBJECTIVES

5.1 Primary Objective

To determine whether during a pandemic, for adults (≥16 years) hospitalised with an influenza-like illness, a 5-day course of dexamethasone started within 24 hours of admission to hospital, in addition to standard care, is associated with a lower risk of death or admission to intensive care compared to placebo.

5.2 Secondary Objectives

To determine whether dexamethasone given in addition to standard care is associated with a reduction in the length of hospital stay, the frequency of hospital readmission and/or the frequency of GP consultations after discharge compared to placebo. If dexamethasone is effective, the study will also evaluate its cost-effectiveness.

6 TRIAL DESIGN

6.1 Summary of Trial Design

The ASAP trial is a pragmatic multi-centre double-blind randomised placebo-controlled trial. The trial design is based on the event of a high-severity pandemic; this being the default position at the start of a pandemic when the severity of a pandemic may not yet be apparent.

The trial will be set-up pre-pandemic. Once set-up is complete and the required approvals have been obtained, the trial will be placed into ‘hibernation’. It will be activated during an influenza pandemic only if instructed by the National Institute for Health Research (NIHR). During the hibernation phase, regular review (at least annually) of trial procedures and sites will ensure that the trial is maintained in a state in which it can be rapidly activated to start recruitment in the event of a pandemic. If the NIHR activate the trial it will move to a pre-activation phase of 4-6 weeks. This final phase of trial set-up will include production and distribution of the trial drug and trial materials, finalisation of trial procedures, and a check of site readiness prior to beginning recruitment. A summary of the trial phases is shown in Figure 1.
Figure 1: Phases of ASAP trial

- **SET-UP**
  Sites selected, approvals gained, processes established.

- **HIBERNATION**
  Trial maintained in 'ready to go' state with regular review of trial procedures and trial sites

- **PRE-ACTIVATION (4-6 weeks)**
  Finalisation of trial procedures, activation of IMP manufacture, final check of trial sites

- **ACTIVATION (approx. 6 weeks)**
  Recruitment of trial participants

Based on a high-severity pandemic the trial will recruit 2200 patients, and flexibility has been included in the design of this trial to allow for pandemics of lower severity. Detailed information can be found in the Statistical Analysis Plan. The final sample size will be determined in conjunction with the Trial Steering Committee during the activation phase of the trial, once information about the severity of the pandemic is available. It is anticipated that there will be up to 50 centres participating in the UK, covering a wide geographical spread.

Adults (≥16 years) admitted to hospital with an influenza-like illness will be screened for entry into the trial within 24 hours of admission to hospital. Once consent for trial participation has been obtained, eligible patients will be randomised into the trial. Participants will be allocated to receive either dexamethasone or placebo. Both will be given as a liquid (orally or via a nasogastric feeding tube) once a day for 5 days whilst the participant is in hospital, or continued at home if the participant is discharged within 5 days of admission to hospital. All other clinical care will be according to national clinical management guidelines for pandemic influenza.

Routinely available data recorded in hospital records at the time of hospital admission will be collected once consent for trial participation has been obtained. Data on outcome will be collected from hospital
records upon discharge from hospital, or on Day 30 whichever is sooner (Day 1 = day of admission to hospital).

Participants will be sent a postal follow-up questionnaire to complete 30 days after hospital discharge. This will ask whether they have consulted their GP or been readmitted to hospital since being discharged from hospital. In addition, for those who were discharged within 5 days of admission and given their trial treatment to take home, information about treatment compliance will be requested. Participants who do not return this follow-up questionnaire within seven days of the expected completion date will be contacted by telephone by a member of the Nottingham Clinical Trials Unit (NCTU) to request the information. If a participant remains hospitalised at Day 60, completion of the follow-up questionnaire is not required. Patient outcome data for these patients will be collected from hospital-based system records.

Participants do not have any additional study visits.

Participants are considered to be in the trial once the trial treatment pack label has been completed (randomisation) until the follow-up questionnaire has been received by the NCTU (or, when a participant, who fails to return the questionnaire, provides the answers over the telephone instead). For any participants that die, inclusion in the trial will be from randomisation until the date of the participant’s death. The participant will be considered lost to follow-up if the questionnaire is not returned and the NCTU are unable to contact the participant by telephone.

Please see Figure 2 for an overview of the trial design.
Figure 2: Overview of trial design

Admission to hospital with influenza-like illness during pandemic & meets eligibility criteria

Obtain consent at admission
Randomise (Day 1)

Allocated to dexamethasone 6mg once daily for 5 days (Day 1-5)
Allocated to placebo once daily for 5 days (Day 1-5)

Collection of admission data from hospital records (Day 1)

Collection of outcome data from hospital notes and health care information systems (Upon discharge or Day 30*)

Completion of postal questionnaire**
Date of discharge + 30 days

*Data collected at discharge or Day 30 if the patient remains hospitalised, whichever is sooner. In event of death data will also be collected.
** For patients hospitalised ≥60 days, no follow-up questionnaire is required; patient outcome data will be collected from hospital-based systems.
6.2 Outcome measures

6.2.1 Primary outcome
Admission to intensive care unit or death, within 30 days of admission to hospital.

6.2.2 Secondary outcomes
1. Length of stay in intensive care unit
2. Readmission to hospital within 30 days of hospital discharge
3. GP consultations within 30 days of hospital discharge
4. Length of stay in hospital
5. Death within 30 days of admission to hospital
6. Admission to intensive care unit within 30 days of admission to hospital

The design and analysis of the trial includes the flexibility to allow for pandemics of different severity. The outcome measures described in this section relate to a high-severity pandemic. Further information on the outcome measures, including those for a pandemic of low/moderate severity, can be found in section 9.

6.3 Trial Participants

6.3.1 Overall Description of Trial Participants
Adults (≥16 years) admitted to hospital with a clinical diagnosis of an influenza-like illness during a pandemic.

6.3.2 Inclusion Criteria
During an influenza pandemic, patients are eligible for entry into the trial if they:
- are ≥ 16 years of age
- have been admitted to hospital within the previous 24 hours with a clinical diagnosis of an influenza-like illness
- have given consent (see section 6.4.2)

6.3.3 Exclusion Criteria
Patients are not eligible for the trial if ANY of the following apply at the time of admission to hospital:
- known to be taking oral or IV corticosteroid treatment
- require treatment with oral or intravenous corticosteroids upon admission to hospital as standard treatment for comorbid illness
- known to be on insulin or oral medication for the treatment of diabetes mellitus
- known contra-indication to dexamethasone or any of the excipients (please refer to current version of SPC)

Where a patient is entered into the trial and later found to meet any of the exclusion criteria detailed above, continuation of trial treatment will be discontinued. Data will continue to be collected unless the participant specifically withdraws their consent to this. Please see section 7.5 for further information.

© Queen’s Printer and Controller of HMSO 2015. This work was produced by Lim et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
6.4 Study Procedures

A summary and timing of the study procedures is shown in Table 1.

Table 1: Study procedures and data collection in the ASAP trial

<table>
<thead>
<tr>
<th>Assessments</th>
<th>Day 1 Screening and enrolment</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
<th>Day 5</th>
<th>Hospital discharge/ Day 30*</th>
<th>Hospital discharge + 30 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screen for eligibility</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obtain written consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomise</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete hospital admission information</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administer trial treatment</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obtain written consent for patients that lacked capacity at enrolment</td>
<td>X*</td>
<td>X*</td>
<td>X*</td>
<td>X*</td>
<td>X*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collection of primary and secondary outcome data from hospital notes*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collect follow-up outcomes from postal questionnaire</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X**</td>
<td></td>
</tr>
<tr>
<td>Serious Adverse Event</td>
<td>Collect from randomisation throughout trial. See section 8 for information on safety reporting requirements.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Data collected at hospital discharge when the discharge is less than 30 days since admission. Data collected at Day 30 if the participant is still in hospital at Day 30.

** Not required if participant is hospitalised ≥ 60 days.

This applies ONLY to those participants that lacked capacity to consent at enrolment. For these participants, written consent must be sought as soon as practicable following the emergency treatment and prior to the patient being discharged from hospital.

6.4.1 Screening and Eligibility Assessment

During a pandemic, adults (≥16 years) admitted to hospital with a clinical diagnosis of an influenza-like illness and who meet the trial inclusion criteria will be identified by the clinical admitting team. Clinical nurses who admit patients with influenza will be trained to provide information about the trial to patients and their families.

Pre-prepared advertising material approved by the relevant ethics committee will be used during the activation phase to raise public awareness of the trial.

6.4.2 Consent

The challenges of obtaining consent for a trial of an acute intervention in an emergency setting within the context of a pandemic are recognised.
Severe pandemic influenza constitutes a medical emergency; these patients can deteriorate rapidly and dramatically – the average time from hospital admission to ICU admission was 1 day in the 2009 pandemic. In addition, the context of a pandemic means that acute health care resources will be exceptionally stretched, through a combination of high healthcare demand and high levels of staff sickness. These challenges to the clinical service will also impact significantly on research delivery. Recruitment to the ASAP trial must not result in any significant delay to patient care, either to the potential participant or to other patients not being approached about the trial. Therefore consent for trial participation needs to be integrated into routine clinical care during a pandemic. This means approaching patients and their families whilst they are being assessed and triaged at hospital admission, and offering participation in a way that minimises disruption to patient care. Thus written consent for the trial will be obtained from potential participants using a short, single page combined information sheet and consent form at hospital admission points (see Figure 3). A full information leaflet will also be given to participants to read at a later time.

Figure 3: Procedure for obtaining consent for the ASAP trial

---

**ENROLMENT AND RANDOMISATION**

Potential participant meets eligibility criteria

Patient has capacity

Emergency situation in which it is not medically appropriate to delay start of treatment?

Yes

One clinician independent of the trial to decide in patient’s best interests

No

Written consent

**ENROLMENT AND RANDOMISATION**

WRITTEN CONSENT FROM PARTICIPANT (IF CAPACITY HAS BEEN RECOVERED) OR PERSONAL LEGAL REPRESENTATIVE* AS SOON AS PRACTICABLE TO DO SO

* Personal Legal Representative can be a partner, friend or relative
6.4.2.1 Patients with capacity to consent (non-emergency situation)

During a pandemic the health service will be in crisis, and triage of patients with influenza-like illness at hospital admission will mean there will be limited time in which to obtain consent from patients. Thus potential participants will have a brief explanation of the trial and be provided with brief written information about the trial in the form of a single page combined information sheet and consent form. After the trial explanation they will be asked if they are willing to be recruited. If they say yes they will be asked to sign the consent form section on the patient information sheet.

Specifically, the responsible doctor or an appropriately trained nurse will explain to the patient that they will receive the usual care for influenza but that in addition to this, they can be enrolled in a research study that aims to improve the treatment of patients with influenza during a pandemic. It will be explained that the study is being undertaken to see whether using a steroid drug called dexamethasone will help patients with influenza infection by reducing the number of patients who have severe outcomes (such as death or admission to intensive care) or by shortening length of stay in hospital. The doctor or an appropriately trained nurse will explain that, in some studies, dexamethasone has been shown to improve outcome for patients with pneumonia or severe 'blood poisoning', and that whilst we hope it will also improve recovery after influenza infection, at present we cannot be sure about this. It will also be explained that if they agree to take part in the study, they will be given a liquid solution once a day for 5 days of either dexamethasone or placebo orally, or if medicines cannot be taken orally, via a feeding tube. Also, they will be sent a short postal questionnaire to complete.

The patient information sheet and consent form will be produced in triplicate copy format; 1 copy for the participant, 1 copy for the patient’s medical notes and 1 copy for the Investigator Site File.

The patient will also be given a full information leaflet to keep, which will explain that they can withdraw from the trial at any stage, if they wish.

Once written consent has been given, the patient will be randomised (see section 6.4.3) and trial treatment commenced.

6.4.2.2 Patient with capacity to consent (emergency situation)

Where a patient has capacity to consent but is in an emergency situation whereby it is not medically appropriate to delay the start of treatment, one independent doctor should consider the patient’s eligibility criteria and any known views of the patient about trial participation and decide whether or not to enroll the patient into the trial.

Once the decision has been made to enter the patient into the trial this must be documented by the clinician in the patient's medical notes. The participant may then be randomised and trial treatment commenced. Written consent must be sought later (see section 6.4.2.4)

6.4.2.3 Patients without capacity to consent

Patients admitted to hospital with influenza may have impaired consciousness, may be confused, or may have an underlying condition such as dementia that impairs their capacity to give properly informed consent. In accordance with the regulations concerning emergency situations where the treatment to be given as part of the trial needs to be given urgently and time does not allow for consent to be obtained, incapacitated patients may be entered into the trial.

Lack of capacity should be determined by the patient’s attending clinician.

If the patient lacks capacity to give meaningful consent one independent doctor should consider the patient’s eligibility criteria and any known views of the patient about trial participation and decide whether or not to enroll the patient into the trial.

The consent decision must be documented in the patient’s medical notes.

Once consent has been given, the participant will be randomised and trial treatment commenced. Written consent must be sought later (see section 6.4.2.4)
6.4.2.4 Written consent for patients that lacked capacity at enrolment and emergency situations

For patients that lack capacity to consent at enrolment or patients with capacity that are entered into the trial under emergency situation regulations, written consent must be obtained by a doctor or appropriately trained nurse from the participant (if capacity has been recovered) or Personal Legal Representative as soon as it is practicable to do so.

A Personal Legal Representative may be a partner, friend or relative.

The participant’s decision to withdraw would overrule any decision made by a doctor or Personal Legal Representative.

6.4.3 Randomisation

Batches of treatment packs will be supplied directly to trial sites from one or more manufacturing units. Each batch will contain a number of sealed treatment packs in a consecutively numbered series.

The following will be included in the treatment pack:
- A 75ml bottle of either dexamethasone 2mg/5ml or placebo (sufficient for 5 days of treatment)
- Instructions for the take home pack (for participants discharged within 5 days of admission)
- Administration instructions
- A spoon for drug administration
- A trial wristband to enable identification of trial participants during hospital transfers

Trial treatment packs will be available in each area where patients with influenza will be admitted during a pandemic. The two treatments, dexamethasone and placebo, will be indistinguishable. Each treatment pack will be labelled with the trial name and a unique identification number. This will be the Participant’s ID Number. NCTU will generate and hold the randomisation sequence according to their SOP.

Once consent for trial participation has been obtained, allocation to trial treatment will be by taking the next in the series of treatment packs at that area each participating site. The trial pack label will be completed and the trial treatment prescribed.

Treatment will be administered as soon as possible, as an addition to standard care.

Participants will be considered to be in the trial once the pack label has been completed regardless of whether or not they take any allocated treatment.

Packs which have been tampered with will be removed from the trial, and any packs used out of sequence will be investigated to ascertain why this happened and whether there was any potential for bias.

The following steps will be taken to guard against participants being randomised into the study more than once:
- Site staff obtaining consent from trial participants at hospital admission points will be trained to ask patients if they have previously participated in the study.
- Reminders of the need to check with patients about previous participation in the study will be in place for clinical staff at hospital admission points.

However given the mechanism of randomisation and the circumstances in a pandemic, it is not possible to completely remove the possibility that someone could be randomised more than once. The analytical approach to deal with this is described in section 9.1.

6.4.4 Collection of hospital admission data

Once consent has been obtained, routinely available data recorded in hospital notes at the time of hospital admission will be recorded on the Case Report Form (CRF) by site staff. This will include patient contact details, patient demographics, time of onset of symptoms, prior treatment, routinely collected clinical observations and test results.
6.4.5 Subsequent assessments

Participants will not have any additional study visits. Data will be collected as follows:

**Hospital discharge or Day 30**

At hospital discharge, or Day 30 if the participant remains in hospital, outcome data will be collected from the medical notes by research staff at site and recorded on the CRF. This will include patient discharge status, critical care admission, in-hospital treatments including IMP compliance and relevant routinely obtained microbiological test results.

A regular check of hospital systems will need to be performed by site staff to ascertain patient status, including outcome information for those patients hospitalised ≥60 days.

**Follow-up**

Participants will be asked to complete a postal follow-up questionnaire 30 days after being discharged from hospital. For any participant who remains hospitalised at Day 60 no follow-up questionnaire is required.

The questionnaire will ask about any GP consultations or hospital readmissions within 30 days of discharge from hospital. In addition, for participants who are discharged within 5 days of admission and given their trial treatment to take home, information about treatment compliance will also be requested. The questionnaire will be posted from the NCTU to trial participants, with a prepaid and addressed envelope to return to the NCTU.

Any participants who do not return the questionnaire within 14 days of the due date for completion will be contacted by telephone by the NCTU. The participant will be considered lost to follow-up if the questionnaire is not returned, and they have either not been contactable by telephone or have declined to complete the questionnaire by telephone.

Identifiable data will be collected for the purpose of the follow-up and the patient’s details will be registered with the Health and Social Care Information Centre (HSCIC) to find out how they are doing after they have left hospital.

6.4.6 Maintenance of randomisation codes and procedures for unblinding

Clinicians, participants and outcome assessors (research team) will be blinded to the treatment allocation.

The randomisation schedule will be stored centrally on a restricted area of the university’s network storage. Access will be restricted to the IT team at the NCTU and central university Information Services’ support staff. The research team will not have access to this.

In general there should be no need to unblind the allocated treatment. If a contra-indication to dexamethasone develops after randomisation (e.g. evidence of severe drug reaction), the trial treatment should simply be stopped. Unblinding should happen only in those rare cases where the doctor believes that clinical management depends importantly upon knowledge of whether the participant received dexamethasone or placebo. In those few cases where urgent unblinding is considered necessary, the date and reason for breaking the code will be recorded. It is recommended that any decision to unblind is discussed with the coordinating centre prior to this being done.

An emergency 24 hour trial contact number for unblinding purposes will be supplied to trial sites upon activation of the trial.

6.5 Definition of End of Trial

The end of trial is the date of receipt of the last follow-up information (questionnaire or, for any patient hospitalised more than 60 days, the date of obtaining patient outcome data from hospital-based system records).
6.6 Discontinuation of trial treatment or withdrawal of participants

Each participant has the right to withdraw from the study at any time. In addition, the investigator may discontinue study treatment at any time if they consider it necessary for any reason including:

- Ineligibility (either arising during the study or retrospective having been overlooked at enrolment)
- Disease progression which requires discontinuation of the study medication or results in inability to continue to comply with study procedures
- Consent withdrawn

6.6.1 Discontinuation of trial treatment

A participant may discontinue treatment either at their own request, or if it is felt in their best interest by the attending clinician. A participant who discontinues treatment (for whatever reason) will remain in the trial for the purpose of collection of follow-up data, unless they have specifically requested withdrawal from further follow-up (see section 6.6.2).

Each participant has the right to discontinue trial treatment at any time. If this happens, they will receive standard care. Participant’s data will be analysed in their allocated group as “intention to treat” regardless of whether or not they received the intervention.

6.6.2 Withdrawal from the trial

Each participant has the right to withdraw from the study at any time. For those participants without capacity to consent to the trial at the time of admission and who were consented by a legal representative, withdrawal from the trial may either be at the participant’s own request (if they regain capacity) or at the request of their relative/legal representative. The participant and the relative/legal representative will be made aware that this will not affect the participant’s future care.

The reasons for leaving the study will be requested and recorded, but participants are not obliged to give reasons. Participants will be assured that withdrawal will not affect the future care they receive. They will be informed that data collected up to the point of withdrawal will be retained and may be used in the final analysis and that their NHS number will be registered with the Health and Social Care Information Centre (HSCIC) to follow them up after they leave hospital (unless specifically requested not to do so), but they will not be directly contacted for the purpose of obtaining follow-up information. There will be no replacement of participants who withdraw.

6.7 Source Data

Source documents are original documents, data, and records from which participants’ CRF data are obtained. These include, but are not limited to, hospital records and clinical charts.

CRF entries will be considered source data if the CRF is the site of the original recording (e.g. there is no other written or electronic record of data). In this trial the follow-up questionnaire will be used as the source document for obtaining information about secondary outcome measures (re-admission to hospital and/or consultation of GP within 30 days of hospital discharge).

All documents will be stored safely in confidential conditions. On all study-specific documents, other than the signed consent document, the participant will be referred to by the unique participant ID number, not by name.

7 TREATMENT OF TRIAL PARTICIPANTS

7.1 Description and manufacture of trial treatment

*Intervention:* Dexamethasone 6 mg as a liquid solution (15ml) once daily for 5 days, administered orally or via enteral feeding tube.

*Control:* Matched placebo solution (15ml) once daily for 5 days, administered orally or via enteral feeding tube.
Dexsol (Dexamethasone) 2mg/5ml Oral Solution manufactured by Rosemont Pharmaceuticals Ltd (PL 00427/0137) will be used in this trial. Rosemont will also manufacture a matching placebo formulation.

Inactive ingredients in the trial treatment (active and placebo): Benzoic acid, propylene glycol, citric acid monohydrate, liquid maltitol, garden mint flavour (containing isopropanol and propylene glycol), liquid sorbitol non-crystallising, sodium citrate and purified water.

7.1.1 Dosage
Participants will receive 15ml dexamethasone (6 mg) or placebo as a liquid solution once daily for 5 days, administered orally or via a nasogastric feeding tube.

All other care will be according to national clinical management guidelines for pandemic influenza

First dose of IMP
The first dose of IMP should be given as soon as possible after consent for trial participation has been obtained, regardless of the time of day.

Subsequent doses of IMP
The date when the first dose of IMP is given to the trial participant should be considered as Day 1 of IMP treatment regardless of the time the dose was given. The second dose of IMP should not be given until the following day (Day 2), preferably in the morning. Further doses should ideally be given each morning.

Please note that this means for any patient receiving their first dose of IMP in the early hours of the morning (Day 1), the dose interval between first and second dose will be more than 24 hours. For those patients randomised late evening, the second dose will be given the following morning and thus the dose interval will be shorter, however this is not expected to be less than 8 hours.

7.1.2 Packaging and Labelling
Rosemont will ship bulk supply of dexamethasone and placebo to one or more manufacturing units, who will be set up to provide the randomised final labelling, packaging and release service in order to ensure the short timeline from activation to the start of trial recruitment is met.

The manufacturing units will receive bulk active and placebo bottles from Rosemont. They will over-label a single 75ml bottle according to Annex 13 and pack with written instructions in a clear outer pack so that the primary packaging label can be read through the pack.

The final product will be QP released by the designated person at the manufacturing unit.

An outer dispenser pack will be assembled containing, in number order the finished active and placebo packs. This will allow the trial treatment packs to be removed from the dispenser in sequence order.

The manufacturing unit where the packaging and release occurs will distribute trial supplies to participating sites.

7.2 Storage of Trial Treatment
The trial treatment will be received and stored by the main pharmacy at each hospital for distribution to the point(s) of patient admission within the hospital. Each participating site main hospital pharmacy will take receipt of numbered supplies from one of the manufacturing units.

Trial treatments will be stored at room temperature below 30 °C. In the local pharmacy, all trial treatments should be stored in a secure location. The main hospital pharmacy will supply batches of individual participant packs to Admission Points: areas within their hospital where influenza admissions occur.

7.3 Compliance with Trial Treatment
Compliance with trial treatment for hospitalised participants will be assessed from their medication chart which nursing staff will complete. This information will be collected and recorded on the CRF. If the
participant is discharged before 5 days, they will be instructed to complete their trial treatment at home. Compliance with study medication following discharge will be obtained from information requested in the follow-up postal questionnaire.

Compliance with trial treatment is expected to be good.

7.4 Accountability of the Trial Treatment

The participant packs of trial treatment will be supplied by the manufacturing units to the main hospital pharmacy at participating sites. All movements of study medication between the manufacturing units and main hospital pharmacies will be documented. The main hospital pharmacies will record the distribution of all trial medication to the admission points within the hospital.

An accountability log will be maintained at each admission point within the hospital and will be completed upon allocation of trial treatment pack to a participant. Completed accountability logs will be returned to the main hospital pharmacy.

Unused participant packs will be retrieved and accountability completed, before local destruction.

7.5 Concomitant Medication

Throughout the trial investigators may prescribe any concomitant medications or treatments deemed necessary to provide adequate supportive care except for those listed in the exclusion criteria (see section 6.3.3). If these are required during the five days of IMP administration, the participant will be withdrawn from the trial treatment.

The following specific medications, other than the trial treatment, taken during the study will be recorded in the CRF:

a) antiviral drugs
b) antibiotics
c) corticosteroids given after completion of trial treatment

8 SAFETY REPORTING

The definition of a serious adverse event (SAE) is problematic in the context of the ASAP trial since participants are likely to be critically ill patients and progression of pandemic influenza can lead to significantly life threatening and serious conditions, which are outcomes for this trial.

Events that are part of the natural history of the primary disease process or expected complications of critical illness will not be reportable as serious adverse events.

The principal investigator at a site will need to distinguish between an SAE that is possibly, probably or definitely related to treatment (i.e. a suspected adverse reaction (SAR) – see definition below) and an SAE that arises from disease progression or has another cause.

The study intervention (dexamethasone) is a commonly used drug for which the safety profile is well established. For this reason, only serious unexpected suspected adverse reactions (SUSARS) should be reported on an SAE form for this trial.

The trial will also capture other serious adverse events (SAEs), which are pre-specified outcomes in the trial. These will not be reportable on an SAE form but will be captured on the CRF and include the following:

- Death due to progression of the underlying disease or co-morbid illness
- Admission to the intensive care unit due to progression of the underlying disease or co-morbid illness
- Prolongation of hospital stay due to progression of the underlying disease or co-morbid illness
8.1 Definitions

8.1.1 Serious Adverse Event (SAE)
A serious adverse event is any untoward medical occurrence in a patient administered a medicinal product, which does not necessarily have to have a causal relationship with the treatment (the study medication) that at any dose:

- Results in death,
- Is life-threatening (NOTE: The term "life-threatening" in the definition of "serious" refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.)
- Requires inpatient hospitalisation or prolongation of existing hospitalisation,
- Results in persistent or significant disability/incapacity, or
- Is a congenital anomaly/birth defect.

Other important medical events (NOTE: Other events that may not result in death are not life threatening, or do not require hospitalisation, may be considered a serious adverse event when, based upon appropriate medical judgement, the event may jeopardise the patient and may require medical or surgical intervention to prevent one of the outcomes listed above.)

8.1.2 Serious Adverse Reaction (SAR)
All untoward and unintended responses to a medicinal product related to any dose.

The phrase "responses to a medicinal product" means that a causal relationship between a study medication and an AE is at least a reasonable possibility, i.e., the relationship cannot be ruled out.

All cases judged by either the reporting medically qualified professional or the sponsor as having a reasonable suspected causal relationship to the trial treatment qualify as adverse reactions.

8.1.3 Expected Serious Adverse Reactions (Expected SAR)
An adverse reaction, the nature or severity of which is consistent with the applicable product information.

8.1.4 Suspected Unexpected Serious Adverse Reactions (SUSARs)
A serious adverse reaction, the nature or severity of which is not consistent with the summary of product characteristics. Dexamethasone is an established drug with a well-known safety profile and therefore the occurrence of SUSARs in this trial is unlikely.

8.2 Reporting procedure
Serious unexpected adverse reactions (SUSARs) are expected to be rare in this trial, however all SUSARs should be reported on an SAE form within 24 hours of being made aware of the event to the Sponsor.

The fax number for reporting of SUSARs will be supplied to trial sites once the decision to activate the trial has been made.

All other serious adverse events and serious adverse reactions will not be reported. Where they are a pre-specified outcome for the trial they will be collected on the CRF.

The flow chart in Figure 4 should be used to determine whether an SAE requires reporting on an SAE form.
Figure 4: Flowchart for reporting of serious adverse events

Serious Adverse Event

- Related to IMP?
  - No
    - Do not report. If event is a pre-specified outcome it will be captured on the CRF
  - Yes
    - Serious Adverse Reaction (SAR)
      - Unexpected?*
        - No
          - SUSAR
            - Report on SAE form within 24 hours
        - Yes
          - Do not report. If event is a pre-specified outcome it will be captured on the CRF

* the event is not consistent with the summary of product characteristics
9 STATISTICAL CONSIDERATIONS

A separate detailed statistical analysis plan will be written and approved by the Trial Steering Committee during the set up phase. The trial is planned in anticipation of a high severity pandemic; this represents the most challenging situation for trial execution and also the situation in which the trial results might have the largest public health impact. At the outset of a pandemic, its severity will not necessarily be accurately appreciated. The statistical plan therefore includes the flexibility to address pandemics of different severity. A review of pandemic severity will be conducted by the TSC as the pandemic unfolds. Decisions regarding the final analysis plan and final primary outcome will rest with the TSC. A summary of the plan is described below.

9.1 Description of Statistical Methods

We will compare numbers, age and sex of randomised participants with aggregate summary data of all patients admitted to hospital with influenza-like illness during the study period. We will compare baseline characteristics of the randomised arms using appropriate descriptive statistics. Between-group comparisons for primary and secondary outcomes will be conducted using an intention-to-treat (ITT) approach, implemented using appropriate regression models, and with results presented as point estimates such as a ratio or difference comparing dexamethasone with placebo, with 95% confidence intervals, and exact p-values. Secondary analyses will include additional adjustment for variables displaying an important imbalance at baseline. We anticipate little, if any, missing primary outcome data and therefore will use ITT without imputation as the main approach, and will investigate the influence of any missing data in sensitivity analyses, including multiple imputation. A definition of the pandemic as high, moderate or low severity is expected soon after the end of the first wave, and analysis of the appropriate primary outcome, and such secondary outcome data as are available, will then ensue in time to inform subsequent pandemic waves. All analyses will be conducted using Stata version 11.2 or higher, or MLwiN 2.10 or higher.

It is possible that a small number of participants will be randomised more than once. We will examine baseline (at first randomisation) characteristics and previous treatment allocation(s) of participants randomised more than once using appropriate descriptive statistics. The primary analysis will use treatment allocation and date of the first randomisation. In sensitivity analyses, we will (1) further adjust for variables associated with multiple randomisation (baseline characteristics and initial treatment allocation), and (2) use treatment allocation and date of the last randomisation.

High Severity Pandemic

In a high severity pandemic, the primary composite outcome is admission to intensive care or death by Day 30, and will be analysed using generalised linear modelling for binary outcomes, also allowing for stratification by site. Additionally, death will be reported alone as a secondary outcome.

Low/Moderate Severity Pandemic

In a low/moderate severity pandemic, the primary outcome is time to hospital discharge, right-censored at 30 days, and will be analysed using appropriate (dependent on distribution of the outcome) time-to-event regression modelling, also allowing for stratification by site and for the occurrence of death prior to hospital discharge as a competing event.

Pre-planned sub-group analyses will be conducted for the primary outcome based on the following baseline factors:

1) Duration of symptoms before trial entry: less than 4 days; more than 4 days; not known
2) Clinical diagnosis of pneumonia at trial entry: pneumonia; no pneumonia; not known
3) Underlying co-morbid illness at trial entry (defined as any medical illness requiring active regular treatment): underlying co-morbid disease, no underlying co-morbid disease; not known
4) Severity of influenza at trial entry (severe influenza defined as the presence of 3 or more community triage criteria [28]): severe influenza; not severe influenza; severity unclear/ not known.
Outcomes will be reported descriptively by sub-group category and treatment arm, and formally estimated by fitting interaction terms in the regression models. It is recognised that power to detect sub-group effects is likely to be low, and these analyses will be regarded as exploratory and interpreted with due caution.

9.2 The Number of Participants

The planned sample size of 2200 patients is based on a high severity pandemic along a range of possible scenarios. This flexibility is important as the accuracy of the modelling may only become clear as the pandemic unfolds.

Based on data from the Department of Health, modelling estimates are that, for a high severity pandemic, 35% of those admitted to hospital will die and 25% will be admitted to intensive care. Of those admitted to intensive care, an estimated 50% will die (estimate derived from UK data related to the 2009 pandemic and to community acquired pneumonia). Thus 47.5% will have the composite outcome of death or admission to hospital in the control group. For this scenario, our study would have 90% power to detect a 15% reduction in relative risk of the composite outcome associated with steroids, and a 20% reduction in deaths. Since a high proportion of those admitted to hospital will die and admissions to intensive care will also be high, therefore, an effect size of 15% would be clinically important.

Table 2 presents a range of scenarios centres around a control event rate of 47.5%.

Table 2: Sample size calculations for a high severity pandemic

<table>
<thead>
<tr>
<th>Control event rate</th>
<th>Relative risk reduction with dexamethasone treatment</th>
<th>N* (80% power)</th>
<th>N* (90% power)</th>
</tr>
</thead>
<tbody>
<tr>
<td>35%</td>
<td>20%</td>
<td>1514</td>
<td>2006</td>
</tr>
<tr>
<td></td>
<td>15%</td>
<td>2704</td>
<td>3592</td>
</tr>
<tr>
<td>40%</td>
<td>20%</td>
<td>1242</td>
<td>1644</td>
</tr>
<tr>
<td></td>
<td>15%</td>
<td>2210</td>
<td>2932</td>
</tr>
<tr>
<td>47.5%</td>
<td>20%</td>
<td>940</td>
<td>1242</td>
</tr>
<tr>
<td></td>
<td>15%</td>
<td>1662</td>
<td>2204</td>
</tr>
<tr>
<td>50%</td>
<td>20%</td>
<td>860</td>
<td>1134</td>
</tr>
<tr>
<td></td>
<td>15%</td>
<td>1514</td>
<td>2010</td>
</tr>
</tbody>
</table>

* Sample size estimates in each cell have been inflated by 5%, to allow for lack of compliance and loss to follow-up (both anticipated to be low)

For low and moderate severity pandemics, a Hazard Ratio of 1.25, indicating an increased risk of discharge at any given time, is considered as the minimum clinically relevant change to detect. The sample size estimation method is the log rank test allowing for competing risks, and assumes that in the control group 5% are censored at 30 days, and in both groups, 6% (low severity pandemic) and 10% (moderate severity pandemic) die during hospitalisation. With 90% power and 1% two-side alpha, and allowing for 5% non-collection of primary outcome data, a total of 912 and 924 participants are required to be randomised for low and moderate severity pandemics respectively.

The target sample size for the study is 2200. If the pandemic is of low or moderate severity, it is likely that fewer than 2200 participants will be randomised during the first wave of approximately six weeks duration, although this definition will not be available until after the end of the first wave. If more than 924 participants are randomised in a low/moderate severity pandemic then smaller effect sizes may be detectable.

9.3 Interim Analyses

The objective of the trial is to complete recruitment within the first pandemic wave. Typically, a pandemic wave is of 6 weeks’ duration. Therefore, it is expected that there will be insufficient time to perform a meaningful interim analysis based on efficacy data prior to close of recruitment. An early analysis will be
conducted at the close of recruitment and before the second pandemic wave. Given the timeframes involved, this early analysis will report on the primary outcome and as many other outcomes as possible.

9.4 Procedure for accounting for missing, unused, and spurious data.
The reason for missing data will be checked. Sensitivity analysis will be performed prior to imputation of missing data. If imputation is required, multiple imputation will be considered if data missing are at random. Otherwise, a selection bias collection model within a mixture model framework will be considered.

Both missing data and spurious data will be queried.

10 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS
Direct access will be granted to authorised representatives from the sponsor, NCTU, host institution and the regulatory authorities to permit trial-related monitoring, audits and inspections.

11 QUALITY CONTROL AND QUALITY ASSURANCE PROCEDURES
The study will be conducted in accordance with the current approved protocol, ICH GCP, relevant regulations and standard operating procedures.

Data will be evaluated for compliance with the protocol and accuracy in relation to source documents. Following written standard operating procedures, the monitors will verify that the clinical trial is conducted and data are generated, documented and reported in compliance with the protocol, GCP and the applicable regulatory requirements.

A Trial Steering Committee (TSC) has been established which includes an independent chair, two independent members and patient representatives. The TSC will meet to discuss and agree the final protocol version, and it will approve the Statistical Analysis Plan before the trial data are unblinded.

The TSC have agreed to meet (either in person or by telephone) every three years during the hibernation phase. A yearly report will be produced by the TMG and sent to the TSC. Should any of the information contained in the report warrant a meeting this will be arranged.

The TSC will be responsible for activating the trial in consultation with the TMG, NIHR and Department of Health.

An independent Data Monitoring Committee (DMC) will be established and will act in accordance with the pre-agreed terms of reference. Only the DMC will have access to unblinded data until the final assessment has been completed.

The Trial Management Group (TMG) will be responsible for day-to-day supervision of the study. Membership will include the CI, the trial manager and at least one other member of the NCTU. The TMG will be responsible for ensuring project milestones are achieved. The TMG will meet monthly during the set up phase, 6 monthly during the ‘hibernation’ phase, and every 2 to 8 weeks during the activation phase (depending on need). The TMG will report at least annually to the TSC.

Recruitment rates at sub-study sites will be monitored closely by the Trial Management Group TMG and TSC.

12 ETHICS

12.1 Declaration of Helsinki
The Investigator will ensure that this study is conducted in full conformity with the current revision of the Declaration of Helsinki (last amended October 2000, with additional footnotes added 2002 and 2004).
12.2 ICH Guidelines for Good Clinical Practice
The Investigator will ensure that this study is conducted in full conformity with relevant regulations and with the ICH Guidelines for Good Clinical Practice (CPMP/ICH/135/95) July 1996.

12.3 Approvals
Trial documents including the protocol, consent documentation, participant information sheet, postal questionnaire and any proposed advertising material will be submitted to an appropriate Research Ethics Committee (REC). Required documents will also be submitted to the regulatory authorities (MHRA in the UK), and host institution(s) for written approval.

The Investigator will submit and, where necessary, obtain approval from the above parties for all substantial amendments to the original approved documents.

12.4 Participant Confidentiality
The trial staff will ensure that the participants’ anonymity is maintained. Each participant will be assigned a Participant ID number, allocated at randomisation, for use on trial documents and the trial database. The documents and database will also use the patient’s initials. The patient’s date of birth will also be entered into the database.

The participants will be identified only by participant ID number on the trial database and on the follow-up questionnaire returned to the NCTU. All documents will be stored securely and only accessible by trial staff and authorised personnel. The study will comply with the Data Protection Act.

12.5 Other Ethical Considerations
There are no additional ethical considerations.

13 DATA HANDLING AND RECORD KEEPING
All trial data will be entered onto a trial specific macro system, via a secure web browser session. Access to the system will be restricted and secure using password protection. All data will be stored on a secure server. Access will be restricted by user identifiers and passwords.

Electronic data will be backed up every 24 hours to a remote secure encrypted server.

For the follow up questionnaire and registration of participants with the HSCIC, identifiable information about participants will be held in a separate area of the system. Access to this information will be restricted to those involved in the follow up phase, as authorised by the Chief Investigator. Only the participant number will be used on the follow up questionnaire that will be posted back to NCTU.

14 FINANCING AND INSURANCE
This study is funded through the NIHR Programme NETSCC Pandemic Flu personal award (11/46/14). Nottingham University hospitals NHS Trust will act as the main sponsor for this trial. Delegated responsibilities will be assigned to the NHS trusts taking part in this trial. Standard NHS Indemnity applies.

15 PUBLICATION POLICY
The study has been designed and will be reported according to the CONSORT guidelines. The findings from this study will provide robust evidence for clinicians working in acute medical services including Emergency Departments. Findings will be published in peer-reviewed scientific journals, medical society newsletters and where possible in the local press and media. The results will be presented at national and international meetings.
international conferences. Participants who requested a copy of the report will be sent a lay summary of the study

16 HEALTH ECONOMICS

A provider perspective for costs will be adopted. For patients in both the test and the control arms, management will entail up to 4 different episodes of hospital stays, plus primary care visits following discharge. The cost for each patient is therefore the sum of the following (where IP = inpatient, LOS = length of stay, in days).

- Cost of initial IP admission = cost of IP stay per diem \(*\) LOS1.
- Cost of readmission = cost of IP stay per diem \(*\) LOS2.
- Cost of intensive/critical care = cost of ICU per hour \(*\) LOS3 \(*\) 24
- Cost of intervention-related complications = cost of IP stay per diem \(*\) LOS4.
- Primary care costs = cost per GP consultation \(*\) number of condition-related consultations.

The trial will record the 4 types of IP LOS and GP visits for each patient, enabling calculation of patient specific health system costs (following multiplication by the appropriate units costs).

For patients admitted to critical care, separate national tariffs for critical care which have been developed in relation to the number of organs supported (zero to six, reference costs currency codes XC07Z to XC01Z) will be used to attribute critical care costs weighted by degree of support to each subject under treatment.

From a health outcome point of view, the only difference between the trial arms will be in their death rates. Given the age at death for each patient, the expected total and average life years lost in each arm using conventional life-tables will be calculated.

The results will be expressed as the:
- Average management cost per patient for each arm.
- Incremental cost-effectiveness ratio (mean cost per life year gained, test arm relative to control).

17 REFERENCES

APPENDIX A – TRIAL FLOW CHART

ASSESS FOR ELIGIBILITY: ADULTS (≥16 YEARS) PRESENTING TO HOSPITAL WITH AN INFLUENZA-LIKE ILLNESS DURING A PANDEMIC

EXCLUSION CRITERIA: taking or requiring oral/IV steroids; on insulin or oral medication for diabetes; contraindication to dexamethasone

PERMUTED BLOCK RANDOMISATION (n=2200) with parallel group design

ALLOCATION: SEQUENTIALLY NUMBERED TRIAL DRUG PACKS AVAILABLE LOCALLY

ALLOCATED TO DEXAMETHASONE (n=1100) 6 mg daily for 5 days. Remainder of patient care as per national guidelines.

ALLOCATED TO MATCHED PLACEBO (n=1100) daily for 5 days. Remainder of patient care as per national guidelines.

OUTCOMES

PRIMARY OUTCOME: Proportion admitted to intensive care or died within 30 days of admission to hospital

Secondary outcomes: Length of hospital stay; Death during hospital stay and within 30 days of discharge; Length of stay in intensive care unit >7 days; Readmission within 30 days of hospital discharge; General Practitioner consultation within 30 days of hospital discharge.

FOLLOW UP

POSTAL QUESTIONNAIRE: 30 days following hospital discharge (and telephone follow up of non-responders 14 days later) to determine GP re-consultation and hospital readmission rates.

ANALYSIS BY INTENTION TO TREAT

AT THE OUTSET OF A PANDEMIC, ITS SEVERITY WILL NOT NECESSARILY BE ACCURATELY APPRECIATED. As the pandemic progresses a review of pandemic severity will be conducted by the TSC. Decisions regarding the final analysis plan will rest with the TSC.
APPENDIX B – MECHANISTIC SUB-STUDY: DETERMINING THE INTERACTION OF STEROID THERAPY AND THE HOST

PLEASE NOTE THAT THIS SUB-STUDY WILL ONLY BE CONDUCTED AT THE FOLLOWING SITES:

1) Aintree University Hospital, Liverpool
2) City Hospital, Nottingham
3) Manchester Royal Infirmary
4) Queen’s Medical Centre, Nottingham
5) Royal Liverpool University Hospital
6) Southampton General Hospital

IMPORTANT: THIS APPENDIX IS ONLY APPLICABLE TO THE ABOVE LISTED SITES.

Aims
This mechanistic sub-study aims to address the following key questions in the treatment of influenza:

a) For each patient, what was the point in the natural history of influenza infection at which admission occurred?
b) What effect does steroid have on the natural history of influenza infection defined by clinical phenotype and RNA transcriptomic pattern?
c) Does comparison of the transcriptomic pattern in placebo versus steroid treated arm suggest pro-inflammatory and anti-inflammatory mechanisms are both altered?

Background
The NIHR have recommended that a mechanistic sub-study be conducted as part of the ASAP trial. This sub-study will be conducted in a limited number of pre-selected ASAP trial sites. These sites have been selected as they are considered to have sufficient staff and infrastructural capacity to manage the additional work related to the sub-study without compromise to clinical care delivery or conduct of the main ASAP trial.

The onset of symptoms is highly variable in influenza exposed adults and the severity of symptoms is the result of a complex host-pathogen interaction altered by co-infection and co-morbid illness. Initially, cytokine data were used to describe this interaction, but recent data from a unique human influenza challenge study have fully described the human inflammatory and anti-inflammatory pathways that determine symptom severity in exposed adults. Using whole genome arrays (Affymetrix Human Genome U133A v2), 5076 genes showed altered expression during the 5 days following influenza A exposure. Unsupervised and clinically informed analyses resulted in self-organising maps (clustered gene expression patterns) which showed 8 functionally important gene sets in which activation/inhibition was tightly associated with clinical severity (see reference 4). The study also described the duration in hours between virus exposure and significant difference in self-organising map (SOM) cluster expression between symptomatic/asymptomatic subjects.

Thus, this sub-study will apply the best contemporary (with respect to the time of pandemic declaration) methods to a representative sample (n=200) of ASAP trial participants in order to determine the interaction of steroid therapy and the host and to apply this in interpreting the clinical outcome measured.
Methods/Design

Patients recruited into the ASAP trial at the sub-study sites will be given the opportunity to participate in the sub-study. 200 patients who have received ASAP study medication are required for the sub-study. ASAP trial participants who consent to participation in the sub-study will give two blood samples and have one nasal swab taken for subsequent transcriptomic and microbiological testing. Blood samples will be collected into vacutainer tubes at baseline and 48 hours post first dose of ASAP study medication. These time points are practical and match the best available transcriptomic data and the expected time course of steroid effect on gene expression. These samples can be collected using standard venesection methods and transferred without urgency to frozen storage in the hospital clinical laboratories. These sample collections should therefore be minimally obstructive in the context of a pandemic. The nasal swab for virological confirmation will be obtained at the time of the first blood sample collection. Please see figure 1 for an overview of the sub-study design.

The overarching principle in relation to the conduct of the mechanistic sub-study is that it should not disadvantage or jeopardise conduct of or recruitment into the main ASAP trial. Six sites have been selected to participate in the sub-study and the decision to activate the sub-study and these sites will be determined by the Trial Management Group according to pre-agreed criteria. The ability of these sites to conduct the sub-study will continue to be monitored by the Trial Management Group throughout the recruitment phase.

Figure 1: Overview of the sub-study design

* Blood and nasal samples are required at the latest 4 hours after first dose of study medication so consent must have been obtained prior to the samples being taken.

* Sample should be obtained at 48 hours (+/- 3 hours) or at discharge if this is sooner
Participants and recruitment
All patients recruited into the ASAP trial at sub-study sites will be eligible to participate in the sub-study.

In order to fulfill the sampling requirements, recruitment into the sub-study should only be considered where it is practically possible to obtain consent for the sub-study and take the first blood sample required for the sub-study either before the participant receives their first dose of ASAP study medication or within 4 hours of the first dose of ASAP study medication being administered.

ASAP trial participants will be approached by a doctor or nurse following consent into the ASAP trial, either at the point of recruitment into the ASAP trial or shortly after being recruited into the ASAP trial.

Consent must be obtained for all patients recruited into the sub-study in a similar manner as for the ASAP trial to ensure a representative sample of participants.

A separate sub-study patient information sheet and consent form will be used.

The procedure for obtaining consent for the sub-study is as follows:

Patients with capacity to consent (non-emergency situation)
ASAP trial participants will be provided with a sub-study patient information sheet and a doctor or nurse will give a verbal explanation of the study. It will be clearly stated that the patient is free to withdraw from the sub-study at any time and for any reason without affecting their future care, and with no obligation to give the reason for withdrawal. The ASAP trial participant will be given the opportunity to ask any questions and if they agree to participate in the sub-study they will be asked to sign a consent form. The participant must personally sign and date the latest approved version of the informed consent form before any sub-study procedures are performed. The person obtaining consent must be suitably qualified and experienced, and have been authorised to do so by the ASAP Trial Principal Investigator.

Once written consent has been obtained, the patient will be enrolled onto the sub-study.

Patients with capacity to consent (emergency situation)
In the same manner described in the ASAP trial protocol, where a patient has capacity to consent but is in an emergency situation whereby it is not medically appropriate to delay the start of the ASAP study treatment, one independent doctor should consider the patient’s eligibility criteria and any known views of the patient about participation and decide whether or not to enrol the patient into the sub-study.

Once the decision has been made to enter the patient into the sub-study this must be documented by the clinician in the patient’s medical notes. The participant may then be enrolled into the sub-study. Written consent must be sought later.

Patients without capacity to consent
If, in accordance with the ASAP trial protocol a patient is judged to lack capacity to consent, one independent doctor should consider the patient’s eligibility criteria and any known views of the patient about participation and decide whether or not to enrol the patient into the sub-study.

Once the decision has been made to enter the patient into the sub-study this must be documented by the clinician in the patient’s medical notes. The participant may then be enrolled into the sub-study. Written consent must be sought later.

Written consent for patients that lacked capacity at enrolment and emergency situations
For patients who lack capacity to consent at enrolment or patients with capacity that are entered into the trial under emergency situation regulations, written consent must be obtained by a doctor or an appropriately trained nurse from the participant (if capacity has been recovered) or Personal Legal Representative as soon as it is practicable to do so.

A Personal Legal Representative may be a partner, friend or relative.
The participant’s decision to withdraw from the sub-study would overrule any decision made by a doctor or Personal Legal Representative.

**Sampling requirements**

Sub-study participants will give two blood samples and a nasal swab for sub-study purposes. All samples will be obtained by an appropriately trained doctor or nurse.

Table 1 provides a summary of the samples required.

Table 1: Sub-study sample requirements

<table>
<thead>
<tr>
<th>Time point</th>
<th>Sample</th>
<th>Details</th>
</tr>
</thead>
</table>
| **Baseline** (after recruitment into ASAP trial and before, or within 4 hours of 1st dose of ASAP study medication) | 16 ml peripheral blood | 2 x 2.5 PAXgene tubes (RNA expression analysis)  
1 x 6ml plasma gel tube (corticosteroid pharmacokinetics)  
1 x 5ml serum gel tube (multiplex cytokine array) |
| | Nasal swab | Collected in standard viral transport medium. This sample will be in addition to any nasal swab taken for clinical purposes, but may be taken at the same time-point if appropriate. |
| **Mid-treatment** (48 hours (+/- 3 hours) after 1st dose of study medication, or prior to hospital discharge, whichever is sooner) | 20 ml peripheral blood | 1 x 5ml plasma gel tube (corticosteroid pharmacokinetics)  
1 x 5ml serum gel tube (multiplex cytokine array)  
1 x 10ml EDTA tube (genotyping) |

**Sample collection, storage and transport**

**Blood samples**

A 16ml peripheral blood sample must be obtained before or within 4 hours of the first dose of ASAP study medication being given to the participant. Blood will be collected into 3 different tube types as outlined in Table 1. Of note, the PAXgene tubes should be collected last and should be used along with an extension adapter. Use of the adapter reduces the risk of reflux of the PAXgene preservative liquid during the blood draw.

A second 20ml peripheral blood sample must be obtained mid-treatment (at 48 hours (+/- 3 hours) after the first dose of ASAP study medication, or prior to hospital discharge, whichever is sooner).

Blood samples will be labelled with a unique sample identifier which will encode the study, participant trial ID number and the sample type and time point. All blood samples will be sent to the clinical laboratories at the hospital where the participant has been recruited. PAXgene tubes must stand at room temperature (RT) for at least 3 hours and no longer than 72 hours. They are then transferred to a standard -21°C freezer then when frozen racked and transferred to a -80°C freezer. The initial RT phase enables the RNA stabilisation solution to penetrate cells. The -21°C freeze prevents the glass bottle cracking when taken down to -80°C. Serum gel and plasma gel tubes will be labelled with similar unique identifiers. They should be spun and separated into 500uL aliquots which should be labelled, racked and frozen at -80°C.

All blood samples should be retained at site until recruitment to the sub-study has been completed. Frozen blood samples should then be sent by courier, on dry ice in a single batch to the Liverpool School of Tropical Medicine (LSTM) where they will be stored at -80°C until analysed. A Material Transfer Agreement (MTA) will be established between recruiting sites and LSTM to facilitate this.
Nasal swabs
A nasal swab must be taken on enrolment. Standard virus swabs with associated virological media will be used and provided in study packs to participating sites by the coordinating centre in Liverpool. All swabs will be promptly labelled and frozen to -80°C. All swabs will subsequently be transferred on dry ice to the Department of Virology, Royal Liverpool University Hospital where then will stored until analysis is performed.

Equipment for sampling
All materials related to the mechanistic sub study samples will be purchased by, and packs created in, Liverpool. These study packs will then be sent out to the sub-study sites.

Sample analysis

Blood samples
Once blood samples are received at the Liverpool School of Tropical Medicine, HTA compliant storage and archiving (Procuro system used for laboratory information) of blood samples will be provided in the Liverpool School of Tropical Medicine Respiratory Infection group.

Analysis of samples will be performed in a single batch using either RNA microarray expression analysis or next generation sequencing, depending on which is the most cost-effective method to obtain the data needed at the time analysis is carried out. This is a fast-moving technology and while the current balance would still favour microarray, it is anticipated that this will no longer be the case in a few years.

An inflammatory array of genes expressed during acute influenza (+/- steroids) will be described (using microarray or sequencing technology). These data will inform the clinical severity score, the duration of illness and most importantly will confirm the immune-modulatory effect of steroids

Nasal swabs
The latest test available to detect influenza virus including the pandemic strain will be used; this is expected to be a PCR test, however the specific test cannot be determined until the point of trial activation. After testing, all nasal swabs will be disposed of.

Surplus samples
Consent will be sought from sub-study participants for any remaining samples to be stored and used for future ethically approved research. Where consent has been given remaining samples will be stored in under a storage license from the Human Tissue Authority (HTA). Request for access to these samples for future ethically approved research will be made through the Chief Investigator and lead sub-study Investigator. Any outputs arising from use of these samples must reflect the contributions of both study teams.

Data collection
No additional data over and above that collection for the ASAP trial is required for the sub-study.

Withdrawal
Each sub-study participant has the right to withdraw from the sub-study at any time. In addition, the investigator may withdraw a participant from the sub-study at any time if the investigator considers it necessary for any reason. Any samples already collected for the sub-study would still be used unless specifically requested not to, in which case any samples collected would be destroyed.

The reason for withdrawal from the sub-study will be requested and recorded in the trial database, however participants are not obliged to give reasons.

There will be no replacement of participants who withdraw from the sub-study.
Statistical analyses

Data arising from the sub-study will be analysed by sub-study investigators at the Liverpool School of Tropical Medicine and University Hospital Aintree.

The following assumes that the platform chosen to achieve the stated aims is microarray analysis of the whole blood RNA transcriptome between subjects (placebo vs control) normalised to the transcriptome of a set of healthy volunteers.

All analyses will be conducted in the latest version of R (currently 3.1.0). For analysis of the RNA transcriptome data we will use the latest version of the package Bioconductor (currently version 2.14). An initial normalisation step will be carried out to account for technical variation in the gene expression data between samples. Differential gene expression analysis will be explored between treatment and control samples using the normalised expression data.

- To address aim one, using day zero data, levels of expression of genes that defined temporal stage in the paper by Huang et al. will be summarised using appropriate descriptive statistics in order to define when in the course of flu infection patients were recruited to the study.

- To address aim two comparing steroid with placebo groups, between-group differences in the expression of relevant genes on day 3 will be estimated using appropriate regression models 4.

- To address aim three - functional analysis of genes of interest (those that are differentially expressed between treatment and placebo groups) will be performed to infer the mechanism of action of steroid when given to patients with pandemic influenza; this will be a descriptive analysis.

References


Appendix 2  Consent form

Patient Information Sheet and Consent
The ASAP (Steroids in Adults with Pandemic Influenza) Trial

Does taking a steroid help improve recovery from pandemic flu?
You have been admitted to hospital with influenza-like illness and need urgent care. You will get all the usual treatment for influenza-like illness that we provide at this hospital. As well as this, we would like to include you in a research study to see if a steroid called dexamethasone helps patients hospitalised with pandemic flu. Some studies have shown that this drug improves the outcome in patients with pneumonia or severe ‘blood poisoning’. We do not know if this drug will help with pandemic flu so we are doing this study.

If you agree to take part in the study you will be given study medicine to take for 5 days. This is a liquid and you will take 15ml (about 3 teaspoons) orally once a day. If your standard treatment needs to be given via a feeding tube then the study medicine will also be given to you via the feeding tube. The study medicine will be given in addition to the normal treatment given to patients with flu.

The study medicine will contain either dexamethasone or placebo. Placebo is a dummy medicine containing no active ingredients. Which treatment you receive is determined by chance (i.e. at random). Neither you nor any of the doctors or nurses looking after you will know which treatment you are receiving. Using a placebo helps us to make a fair test between treatments.

Steroids such as dexamethasone are very commonly used drugs. When given for a short time, as in this study, steroids are generally considered safe with few side-effects. If the doctor looking after you feels you should not receive steroids, you will not be eligible to take part in this study.

We will need to collect some information from your medical notes about your stay in hospital and will send this to a central office in Nottingham. We will also send them your contact details and your NHS number so that they can find out how you are doing after you have left hospital and send you a short 5 minute questionnaire to complete one month after you go home from hospital. If you agree to participate in the study your GP will also be informed.

If you want to know more about our study now then we will tell you. But otherwise we will give you an information leaflet to read at a later time which tells you everything you need to know. You do not have to take part and you may change your mind at any time; please just tell your doctor or nurse.

This study has been approved by the South Central – Oxford C Research Ethics Committee (REC).

I confirm that I have been given a copy of the Patient Information Leaflet (version 2.0, dated 11-Feb-2014) and I agree to participate in the ASAP study; for my medical records to be accessed, my GP informed and my contact details and NHS number collected and used for the purpose of the study.

Name of participant ________________ Signature ________________ Date ________________

Name of person taking consent ________________ Signature ________________ Date ________________

Participant ID number when allocated: __________________ NHS or Hospital No. ____________________
Personal Legal Representative* Information Sheet & Consent
*May be a partner, relative or friend

The ASAP (Steroids in Adults with Pandemic Influenza) Trial

Does taking a steroid help improve recovery from pandemic flu?
Your partner/relative/friend has been admitted to hospital with influenza-like illness and needs urgent care. They will get all the usual treatment for influenza-like illness that we provide at this hospital. As well as this, we would like to include them in a research study to see if a steroid called dexamethasone helps patients hospitalised with pandemic flu. Some studies have shown that this drug improves the outcome in patients with pneumonia or severe ‘blood poisoning’. We do not know if this drug will help with pandemic flu so we are doing this study.

If you agree for your partner/relative/friend to take part in the study they will be given study medicine to take for 5 days. This is a liquid and they will take 15ml (about 3 teaspoons) orally once a day. If their standard treatment needs to be given via a feeding tube then the study medicine will also be given to them via the feeding tube. The study medicine will be given in addition to the normal treatment given to patients with flu.

The study medicine will contain either dexamethasone or placebo. Placebo is a dummy medicine containing no active ingredients. Which treatment they receive is determined by chance (i.e. at random). Neither you nor any of the doctors or nurses looking after them will know which treatment they are receiving. Using a placebo helps us to make a fair test between treatments.

Steroids such as dexamethasone are very commonly used drugs. When given for a short time, as in this study, steroids are generally considered safe with few side-effects. If the doctor looking after your partner/relative/friend feels they should not receive steroids, they will not be eligible to take part in this study.

We will need to collect some information from your partner/relative/friend’s medical notes about their stay in hospital and will send this to a central office in Nottingham. We will also send their contact details (we may also send your contact details as well) and NHS number so that they can find out how your partner/relative/friend is doing after they leave hospital and send a short 5 minute questionnaire to complete one month after they go home from hospital. We will also inform their GP.

If you want to know more about our study now then we will tell you. But otherwise we will give you an information leaflet to read at a later time which tells you everything you need to know. Your partner/relative/friend does not have to take part and you/they may change your/their mind at any time; please tell their doctor or nurse if there is a change of mind.

This study has been approved by the South Central – Oxford C Research Ethics Committee (REC).

I confirm that I have been given a copy of the Personal Legal Representative Information Leaflet (version 2.0, dated 11-Feb-2014) and I agree for them to participate in the ASAP study; for their medical records to be accessed, their GP informed and contact details and NHS number collected and used for the purpose of the study.

<table>
<thead>
<tr>
<th>Name of person giving consent</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relationship to participant:</td>
<td>Name of participant:</td>
<td></td>
</tr>
<tr>
<td>Name of person taking consent</td>
<td>Signature</td>
<td>Date</td>
</tr>
</tbody>
</table>

Participant ID number when allocated: ____________ NHS or Hospital No. ____________________
Appendix 3  Information leaflet
What if there is a problem?

If you have a concern or questions about any aspect of this study you should speak to your local study team who will do their best to answer your questions or you can contact the Patient Advice and Liaison Service (PALS); contact details can be found on the back of this leaflet.

If you remain unhappy and wish to complain formally, you can do this through the NHS Complaint Procedure. Details can be obtained from your hospital.

In the event that something goes wrong and you are harmed during the study there are no special compensation arrangements. If you are harmed and this is due to someone’s negligence then you may have grounds for legal action for compensation but you may have to pay your legal costs. The normal National Health Service complaints mechanisms will still be available to you.

Will my taking part be kept confidential?

All information we collect about you will be kept in the strictest confidence. Only persons involved in the conduct or regulation of the study will have access to your personal details. We will also register your NHS number with the Health and Social Care Information Centre to help us follow up your health status. We will have confidentiality and security arrangements in place to ensure your details are dealt with in the strictest confidence. These details will be kept securely, with access restricted. You will not be named or otherwise identified in any study publication.

We will let your GP know that you are taking part in the study.

Who has reviewed the study?

All research in the NHS is looked at by an independent group of people called a Research Ethics Committee, to protect your safety, rights, wellbeing and dignity. This study has been reviewed by the South Central—Oxford C Research Ethics Committee.

The ASAP trial is funded by the National Institute for Health Research (NIHR)
We would like to invite you to take part in our research study.

What is the purpose of the study?

Some studies have shown that a steroid drug called dexamethasone improves the outcome in patients with pneumonia or severe ‘blood poisoning’. There is uncertainty whether this drug might also improve the recovery of patients with severe flu infection. In this study we are trying to find out whether dexamethasone given for 5 days in addition to the normal treatment for flu is beneficial in patients admitted to hospital with flu during a pandemic.

We are asking up to 2200 patients admitted to hospital with a flu-like illness to take part.

What will I have to do?

If you decide to take part in the study you will be given some study medicine to take once a day for 5 days.

The study medicine will contain either:
1) dexamethasone or
2) a placebo (a dummy treatment which looks like the real medicine but contains no active ingredient.)

Using a placebo helps us make a fair comparison between treatments. Neither you nor any of the doctors or nurses looking after you will know which treatment you are receiving (although if they need to find out they can do so). The decision about which treatment you receive will be decided by chance (rather like tossing a coin) and neither you nor your doctor will be able to choose. This is important as it ensures a fair comparison between treatments.

At the end of the study, we will be able to compare if patients who took dexamethasone did better compared to patients who took placebo.

In all instances, you will still receive the standard treatment currently used to treat patients with a flu-like illness.

About the study medicine

The study medicine is a liquid. You will be given a bottle containing enough medicine to last for 5 days.

You will need to take 15ml by mouth once a day for 5 days.

Your doctor will explain how to take your medicine and you need to do this for 5 days. If you leave hospital then you will take the medicine home to continue it at home. You should continue to take your medicine as your doctor tells you to.

What information is collected?

We want to look in your medical notes for information about your illness and the treatment your doctor gives you whilst in hospital. Your doctor will give this to us with your permission.

We would like to find out how you are doing one month after you leave hospital. We will send you a short questionnaire; this will take about 5 minutes to complete. The questionnaire will be posted to you at your home, with a free-post return envelope. Your contact details will be collected and sent to the Coordinating Centre in Nottingham for this purpose.

What will happen after the study?

When you have finished your study medicine you will receive normal care whilst in hospital. If you have left hospital at this point you will not have to do anything. We will contact you with a questionnaire one month after you leave hospital.

Results of the study

The results of the study will be available after it has finished and will usually be published in a scientific journal and be presented at a scientific conference. However, you will not be identified in any report or publication. A summary of the results will also be sent to you.

Possible disadvantages/risks

Steroids are very commonly used drugs. Side effects can include increased appetite, acne, mood changes such as becoming very aggressive, irritable and short tempered with people and rapid mood swings, such as feeling very happy one minute and sad and weepy the next. These are very rare. Scientific studies (trials) of steroids in pneumonia and blood poisoning have shown improved outcomes with steroids (patients less likely to die and reduced length of hospital stay) without any associated major harmful effects. Less reliable studies conducted during the 2009 pandemic have shown mixed results—in some studies patients who received steroids were more likely to die and in other studies patients were no more likely to die, compared to patients who did not receive steroids.

Possible benefits

We cannot promise that the study will help you, but the information that we get from the study might help improve the treatment of patients with pandemic flu in the future.
In Personal Legal Representative* Information Leaflet

Admitted to hospital with flu?

QUESTIONS OR CONCERNS?

If you would like more information, or have any concerns about the study please contact your local research team:

Local research team and PALS contact details to be inserted here:

Who has reviewed the study?

All research in the NHS is looked at by an independent group of people called a Research Ethics Committee, to protect your safety, rights, wellbeing and dignity. This study has been reviewed by the South Central—Oxford C Research Ethics Committee.

Will my partner/friend/relative’s taking part be kept confidential?

All information we collect about your partner/friend/relative will be kept in the strictest confidence. Only persons involved in the conduct or regulation of the study will have access to your partner/friend/relative’s personal details. We will also register their NHS number with the Health and Social Care Information Centre to help us follow up their health status. We would also like to collect your contact detail in case we need to contact you to find out how they are once they have left hospital. We will have confidentiality and security arrangements in place to ensure all details are dealt with in the strictest confidence. These details will be kept securely, with access restricted. Your partner/friend/relative will not be named or otherwise identified in any study publication.

We will let your partner/friend/relative’s GP know that they are taking part in the study.

The ASAP trial is funded by the National Institute for Health Research (NIHR)

APPENDIX 3
Some studies have shown that a steroid drug called dexamethasone improves the outcome in patients with pneumonia or severe ‘blood poisoning’. There is uncertainty whether this drug might also improve the recovery of patients with severe flu infection. In this study we want to find out whether dexamethasone given for 5 days in addition to the normal treatment for flu is beneficial in patients admitted to hospital with flu during a pandemic.

We are asking up to 2200 patients admitted to hospital with a flu-like illness to take part.

What will my partner/relative/friend have to do?

If you agree for your partner/relative/friend to take part in the study they will be given some study medicine to take once a day for 5 days.

The study medication will contain either:

1) dexamethasone or
2) a placebo (a dummy treatment which looks like the real medicine but contains no active ingredient.)

Using a placebo helps us make a fair comparison of the treatments. Neither you, your partner/relative/friend, nor any of the doctors or nurses looking after them will know which treatment they are receiving (although if they need to find out they can do so). The decision about which treatment they receive will be decided by chance (rather like tossing a coin) and neither you, your partner/relative/friend or their doctor will be able to choose. This is important as it ensures a fair comparison between treatments. At the end of the study, we will be able to compare if patients who took dexamethasone did better compared to patients who took placebo.

In all instances, your partner/relative/friend will still receive the standard treatment currently used to treat patients with a flu-like illness.

What is the purpose of the study?

The study medicine is a liquid. They will be given a bottle containing enough medicine to last for 5 days. Your partner/relative/friend will need to take 15 ml by mouth once a day for 5 days. If they are too poorly to take their standard treatment by mouth, doctors may use a feeding tube to give them treatment directly to their stomach. If this happens, the feeding tube will also be used to give the study medicine.

If your partner/relative/friend stays in hospital less than 5 days then they will take the medicine home to continue it at home. They should continue to take the medicine as their doctor tells them to.

What information is collected?

We want to look in your partner/relative/friend’s medical notes for information about their illness and the treatment their doctor gives them whilst in hospital. Their doctor will give this to us with your permission.

We would like to find out how your partner/relative/friend is doing one month after they leave hospital. We will send them a short questionnaire; this will take about 5 minutes to complete. The questionnaire will be posted to your partner/relative/friend at their home, with a freepost return envelope. Their/Your contact details will be sent to the Coordinating Centre in Nottingham for this purpose. If we do not hear from them after a time, we will attempt to contact them by telephone to find out if they have received the questionnaire and how they are doing.

Possible disadvantages/risks

Steroids are very commonly used drugs. Side effects can include increased appetite, acne, mood changes such as becoming very aggressive, irritable and short tempered with people and rapid mood swings, such as feeling very happy one minute and then very sad and weepy the next. These are very rare. Scientific studies (trials) of steroids in pneumonia and blood poisoning have shown improved outcomes with steroids (patients less likely to die and reduced length of hospital stay) without any associated major harmful effects. Less reliable studies conducted during the 2009 pandemic have shown mixed results—in some studies patients who received steroids were more likely to die and in other studies patients were no more likely to die, compared to patients who did not receive steroids.

Possible benefits

We cannot promise that the study will help your partner/friend/relative, but the information we get from the study might help improve the treatment of patients with pandemic flu in the future.

What happens after the study?

When your partner/friend/relative has finished their study medicine they will receive normal care whilst in hospital. If they have left hospital at this point they will not have to do anything. We will contact them with a questionnaire one month after they leave hospital.

Results of the study

The results of the study will be available after it has finished and will usually be published in a scientific journal and be presented at a scientific conference. However, your partner/relative/friend will not be identified in any report or publication. A summary of the results will also be sent to your partner/relative/friend.
Appendix 4  Follow-up questionnaire

QUESTIONNAIRE FOR YOUR COMPLETION

Dear [participant name]

You may remember that when you were recently admitted to hospital with a flu-like illness you agreed to participate in the ASAP trial – a study investigating low dose steroids in adults with pandemic flu.

As part of this study we would like to know how you have been since you left hospital and would be grateful if you would complete the enclosed short questionnaire.

Your answers to the questions are extremely valuable and will help us understand how well the study treatment worked. We also want to remind you that your answers will be kept completely confidential. Therefore, your answers will in no way affect your future care.

There are no right or wrong answers.

INSTRUCTIONS

- Please complete the enclosed questionnaire
- Once completed, please return to the research team as soon as possible in the pre-paid envelope provided.

If you need help filling in this questionnaire, please feel free to discuss this with a relative or friend.

We will attempt to telephone you if we have not received the questionnaire back within 14 days.

If you have any questions about this questionnaire please contact the research team at the co-ordinating centre on [contact number].

Thank you in advance for completing this questionnaire.

ASAP Follow-up questionnaire Final Version 1.0 dated 23-Jul-2013
Our records show that you were discharged from hospital on: 
XX-XXX-XXXX

1. How many times have you consulted your GP for any reason in the 30 days after discharge from hospital?

   ANSWER (please tick one):
   
   0 [ ] 1 [ ] 2 [ ] 3 [ ] 4 [ ] More than 4 [ ] times
   If more than 4 times, how many? [ ]

2. How many times have you been back to hospital to seek medical care in the 30 days after discharge from hospital?

   ANSWER (please tick one):
   
   0 [ ] 1 [ ] 2 [ ] 3 [ ] 4 [ ] More than 4 [ ] times
   If more than 4 times, how many? [ ]

3. Did you take your study medication home with you?

   ANSWER (please tick one):
   
   No [ ] If no, there are no further questions
   Yes [ ] If yes, please answer question 4

4. If you answered yes to question 3, did you manage to finish the treatment course? (If so, the bottle containing the study medication should be empty)

   ANSWER (please tick one):
   
   Yes, I completed the course at home [ ]
   No, I did not complete the course [ ]

THANK YOU FOR COMPLETING THIS QUESTIONNAIRE

PLEASE NOW POST THIS BACK TO US USING THE PRE-PAID ENVELOPE PROVIDED

ASAP Follow-up questionnaire Final Version 1.0 dated 23-Jul-2013
QUESTIONNAIRE FOR YOUR COMPLETION

Dear [relative’s name]

You may remember that when [participant’s name] was recently admitted to hospital with a flu-like illness you agreed for them to participate in the ASAP trial – a study investigating low dose steroids in adults with pandemic flu.

As part of this study we would like to know how [participant’s name] has been since they left hospital and would be grateful if you would complete the enclosed short questionnaire on their behalf or forward this to them for their completion.

Your answers to the questions are extremely valuable and will help us understand how well the study treatment worked. We also want to remind you that your answers will be kept completely confidential. Therefore, your answers will in no way affect your future care.

There are no right or wrong answers.

INSTRUCTIONS

- Please complete the enclosed questionnaire
- Once completed, please return to the research team as soon as possible in the pre-paid envelope provided.

If you need help filling in this questionnaire, please feel free to discuss this with a relative or friend.

We will attempt to telephone you if we have not received the questionnaire back within 14 days.

If you have any questions about this questionnaire please contact the research team at the co-ordinating centre on [contact number].

Thank you in advance for completing this questionnaire.
Please note that if you are completing this form on behalf of someone else, the following questions relate to that person.

**Our records show that you were discharged from hospital on:**
[Date]

1. How many times have you consulted your *GP for any reason* in the 30 days after discharge from hospital?

   **ANSWER** (please tick one):
   - [ ] 0  
   - [ ] 1  
   - [ ] 2  
   - [ ] 3  
   - [ ] 4  
   - [ ] More than 4 times
   *If more than 4 times, how many? [  ]*

2. How many times have you been back to hospital to seek medical care in the 30 days after discharge from hospital?

   **ANSWER** (please tick one):
   - [ ] 0  
   - [ ] 1  
   - [ ] 2  
   - [ ] 3  
   - [ ] 4  
   - [ ] More than 4 times
   *If more than 4 times, how many? [  ]*

3. Did you take your study medication home with you?

   **ANSWER** (please tick one):
   - [ ] No  
   - [ ] If no, there are no further questions
   - [ ] Yes  
   - [ ] If yes, please answer question 4

4. If you answered yes to question 3, did you manage to finish the treatment course? (If so, the bottle containing the study medication should be empty)

   **ANSWER** (please tick one):
   - [ ] Yes, I completed the course at home
   - [ ] No, I did not complete the course

**THANK YOU FOR COMPLETING THIS QUESTIONNAIRE**

**PLEASE NOW POST THIS BACK TO US USING THE PRE-PAID ENVELOPE PROVIDED**
### Appendix 5  Participating sites

#### i) Sites with NHS permission

<table>
<thead>
<tr>
<th>NHS trust</th>
<th>Principal Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blackpool Teaching Hospitals NHS Foundation Trust</td>
<td>Dr Jason Cuppitt</td>
</tr>
<tr>
<td>Central Manchester University Hospitals NHS Foundation Trust</td>
<td>Professor Mark Woodhead</td>
</tr>
<tr>
<td>Chelsea and Westminster Hospitals NHS Foundation Trust</td>
<td>Dr Hannah Skene</td>
</tr>
<tr>
<td>Chesterfield Royal Hospital NHS Foundation Trust</td>
<td>Dr Anthony Darby</td>
</tr>
<tr>
<td>Countess of Chester Hospital NHS Foundation Trust</td>
<td>Dr Stephen Scott</td>
</tr>
<tr>
<td>Derby Hospitals NHS Foundation Trust</td>
<td>Dr Tom Bewick</td>
</tr>
<tr>
<td>Gateshead Health NHS Foundation Trust</td>
<td>Dr Helen Curtis</td>
</tr>
<tr>
<td>Heart of England NHS Foundation Trust</td>
<td>Dr Neil Jenkins</td>
</tr>
<tr>
<td>Hull and East Yorkshire Hospitals NHS Trust</td>
<td>Dr Gavin Barlow</td>
</tr>
<tr>
<td>The Leeds Teaching Hospitals NHS Foundation Trust</td>
<td>Dr Jane Minton</td>
</tr>
<tr>
<td>Lothian NHS Board</td>
<td>Dr Adam Hill</td>
</tr>
<tr>
<td>The Newcastle upon Tyne Hospitals NHS Foundation Trust</td>
<td>Dr Ashley Price</td>
</tr>
<tr>
<td>Nottingham University Hospital (Queen’s Medical Centre &amp; City Hospital)</td>
<td>Dr Frank Colley</td>
</tr>
<tr>
<td>Oxford University Hospitals NHS Trust</td>
<td>Dr Matthew Scarborough</td>
</tr>
<tr>
<td>Portsmouth Hospitals NHS Trust</td>
<td>Professor Anoop Chauhan</td>
</tr>
<tr>
<td>Royal Berkshire NHS Foundation Trust</td>
<td>Dr Liza Keating</td>
</tr>
<tr>
<td>Royal Cornwall Hospitals NHS Trust</td>
<td>Dr Jonathan Paddle</td>
</tr>
<tr>
<td>Royal Devon and Exeter NHS Foundation Trust</td>
<td>Dr Bipen Patel</td>
</tr>
<tr>
<td>Royal Free Hampstead NHS Trust</td>
<td>Dr Alison Rodger</td>
</tr>
<tr>
<td>Royal Liverpool and Broadgreen University Hospitals NHS Trust</td>
<td>Dr Andrea Collins</td>
</tr>
<tr>
<td>The Royal Wolverhampton Hospitals NHS Trust</td>
<td>Dr Andrew MacDuff</td>
</tr>
<tr>
<td>Sherwood Forest Hospitals NHS Foundation Trust</td>
<td>Dr Mark Roberts</td>
</tr>
<tr>
<td>South Tees Hospital NHS Foundation Trust</td>
<td>Professor Stephen Bonner</td>
</tr>
<tr>
<td>St George’s Healthcare NHS Trust</td>
<td>Professor Emma Baker</td>
</tr>
<tr>
<td>University Hospitals Coventry and Warwickshire NHS Trust</td>
<td>Dr Magdy Sakr</td>
</tr>
<tr>
<td>University Hospitals of Morecambe Bay NHS Foundation Trust</td>
<td>Dr Asim Ijaz</td>
</tr>
<tr>
<td>University Hospital of North Staffordshire NHS Trust</td>
<td>Dr Mohammed Haris</td>
</tr>
<tr>
<td>Wirral University Teaching Hospitals NHS Foundation Trust</td>
<td>Dr Andrew Wight</td>
</tr>
<tr>
<td>York Teaching Hospitals NHS Foundation Trust</td>
<td>Dr John White</td>
</tr>
</tbody>
</table>
ii) Sites in set-up/intending to participate

<table>
<thead>
<tr>
<th>NHS trust</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aintree University Hospitals NHS Foundation Trust,</td>
</tr>
<tr>
<td>Cambridge University Hospitals NHS Foundation Trust</td>
</tr>
<tr>
<td>Medway NHS Foundation Trust</td>
</tr>
<tr>
<td>NHS Grampian</td>
</tr>
<tr>
<td>NHS Greater Glasgow and Clyde</td>
</tr>
<tr>
<td>North Bristol NHS Trust</td>
</tr>
<tr>
<td>Salford Royal NHS Foundation Trust</td>
</tr>
<tr>
<td>Sheffield Teaching Hospitals NHS Foundation Trust</td>
</tr>
<tr>
<td>Southampton University Hospitals NHS Trust</td>
</tr>
<tr>
<td>Southend University Hospital NHS Foundation Trust</td>
</tr>
<tr>
<td>University Hospital of South Manchester NHS Foundation Trust</td>
</tr>
</tbody>
</table>